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ABSTRACT 
 
 Biotin metabolism in prokaryotes is directly linked to transcriptional regulation by 
the enzyme biotin protein ligase (BPL). This system is most thoroughly studied and 
characterized in Escherichia coli. Transcription of the E. coli biotin (bio) operon is 
directly regulated by the biotin-protein ligase, BirA, the enzyme that covalently attaches 
biotin to its cognate acceptor proteins. Binding of BirA to the bio operator requires 
dimerization of the protein, which is triggered by BirA-catalyzed synthesis of biotinoyl-
adenylate (biotinoyl-5'-AMP), the obligatory intermediate of the ligation reaction. In this 
thesis I carried out an in-depth analysis of the BirA protein from E. coli using a 
combination of mutational and biochemical analysis. These studies provide the first 
strong evidence that the inter-domain interactions are required for full enzymatic and 
transcriptional functions of this highly dynamic enzyme. 
 In Chapter 2, I describe the isolation and characterization of a new class of 
superrepressor mutant strains of BirA. Such superrepressor BirA proteins would repress 
the biotin operon transcription in vivo at biotin concentrations well below those needed 
for repression by wild-type BirA. Mutant strains having this phenotype were isolated by a 
combined selection-screening approach. The multiple mutations were resolved to give 
several birA superrepressor alleles each having a single mutation all of which showed 
repression dominant over the wild-type allele. All of these mutant strains repressed bio 
operon transcription in vivo at biotin concentrations that gave derepression of the wild-
type strain and retained sufficient ligation activity for growth when overexpressed. All of 
the superrepressor strains except that encoding G154D BirA showed derepression of bio 
operon transcription upon overproduction of a biotin accepting protein. The G154D BirA 
was a lethal mutation in single copy and the purified protein was unable to transfer biotin 
from enzyme bound biotinoyl-adenylate either to the natural acceptor protein or to a 
biotin accepting peptide sequence. Consistent with the transcriptional repression data, 
each of the purified mutant proteins showed increased affinity for the biotin operator 
DNA in electromobility shift assays. Surprisingly, although most of the mutations were 
located in the catalytic domain, all those tested excepting G154D BirA had normal ligase 
activity. Most of the mutations that gave superrepressor phenotypes altered residues 
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located close to the dimerization interface of BirA. However, two mutations were located 
at sites well removed from the interface. The properties of the superrepressor mutants 
strengthen and extend other data indicating that BirA function entails extensive 
interactions among the three domains of the protein and shows that normal ligase activity 
does not ensure normal DNA binding. 
 The BirA biotin protein ligase of E. coli belongs to the winged helix-turn-helix 
(wHTH) family of transcriptional regulators. The N-terminal BirA domain is required for 
both transcriptional regulation of biotin synthesis and biotin protein ligase activity. In 
Chapter 3, I addressed the structural and functional role of the wing of the wHTH motif 
in both BirA functions. A panel of N-terminal deletion mutant proteins, including a 
discrete deletion of the wing motif, were unable to bind DNA. However, all the N-
terminal deletion mutants weakly complemented growth of a ΔbirA strain at low biotin 
concentrations indicating compromised ligase activity. A wing domain chimera was 
constructed by replacing the BirA wing with the nearly isosteric wing of the E. coli 
OmpR transcription factor. Although this chimera BirA was defective in operator 
binding, it was much more efficient in complementation of a ΔbirA strain than was the 
wing-less protein. The enzymatic activities of the wing deletion and chimera proteins in 
the in vitro synthesis of biotinoyl-5ʹ′-AMP differed greatly. The wing deletion BirA 
accumulated an off-pathway compound, ADP, whereas the chimera protein did not.  
Moreover, a single residue alteration in the wing bypasses the deleterious effects caused 
by mutations in the biotin-binding loop of the ligase active site. I believe that the role of 
the wing in the BirA enzymatic reaction is to orient the active site and thereby protect 
biotinoyl-5ʹ′-AMP from attack by solvent. This is the first evidence that the wing domain 
of a wHTH protein can play an important role in enzymatic activity. 
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CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
1.1 THE DISCOVERY OF BIOTIN 
 Biotin, also known as vitamin B7 and vitamin H (H for the German word for hair: 
Haut), is an essential water-soluble vitamin for most organisms that functions as a 
coenzyme in key metabolic reactions. Biotin functions metabolically only as a protein-
bound cofactor that performs essential CO2 transfer reactions in central metabolism. 
However, it took nearly 40 years after its initial discovery for its vitamin activity to be 
realized. Biotin was discovered in 1901 by Wildiers as a growth factor of unknown 
structure termed bios (115). In 1934 Kögl identified biotin as a growth supplement for 
yeast growing in a defined synthetic medium and purified it from egg yolk (62). In 1933 
and 1938, Allison and colleagues (4, 5) independently found that rhizobia showed an 
increase in growth upon addition of biotin, (then named as coenzyme R). In 1941, 
György and his colleagues isolated biotin from liver and demonstrated that it was the 
curative factor in egg-white injury in rats, supported yeast growth, and also a growth and 
respiratory factor for Rhizobia (52, 109, 110). In 1942 Vigneaud and coworkers 
succeeded in obtaining free biotin in crystalline form (111), which led to the chemical 
synthesis of biotin by Harris and colleagues in 1944 (54). Virtually all of the biotin that is 
utilized today is derived by chemical synthesis and is included in vitamin tablets and 
animal feeds because mammals and birds are biotin auxotrophs. Extensive research in 
several microbial systems has gone into understanding biotin biosynthesis pathways and 
the regulatory mechanisms. These studies are important because biotin has evolved into a 
key coenzyme essential in carbon dioxide fixation in several metabolic processes in all 
three domains of life. Detailed understanding of these regulatory pathways will allow 
development of a system that could result in an efficient mode to produce biotin by 
biosynthesis. 
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1.2 THE METABOLIC ROLE OF BIOTIN 
 Biotin is synthesized by a diverse set of archaea, bacteria, some fungi and plants. 
It is an essential cofactor in major metabolic processes like gluconeogenesis, fatty acid 
synthesis, amino acid metabolism and energy transduction (15). The primary role of 
biotin is to function as a coenzyme for biotin-dependent enzymes. Biotinylated proteins 
play enzymatic roles in three classes of reactions: carboxylation, decarboxylation and 
transcarboxylation. In all three reactions biotin exists in the form of a reactive 
intermediate, 1ʹ′-N-carboxybiotin. The carboxyl group is attached to one of the two 
ureido-nitrogen atoms of the coenzyme. In 1961 the biological function of biotin as a 
cofactor in biotin-dependent carboxylases was described by Lynen and coworkers (69) 
followed by the work of Moss and Lane (74) showing that biotin is a cofactor for several 
different biotin-dependent carboxylases. In the carboxyl-transfer reaction, the carboxyl 
group is transferred to acceptor substrates such as pyruvate and acetyl-CoA to give 
oxaloacetate and malonyl-CoA (Figure 1.1), respectively. The decarboxylation reaction 
was first demonstrated by Schwarz et al. (98) for the oxaloacetate decarboxylase of 
Klebsiella pneumoniae. The decarboxylation of the enzyme-bound carboxy-biotin from 
the donor substrates like oxaloactetate, glutaconyl-CoA or methylmalanoyl-CoA is 
accompanied by the transport of two Na+ into the periplasm and consumption of one 
periplasmically-derived proton (14, 18, 44). Finally, in transcarboxylation reactions the 
carboxylation and decarboxylation reactions are coupled. For example, the reaction 
carried out by methylmalonyl-CoA transcarboxylase (106) uses two substrates, pyruvate 
and (S)-methylmalonyl-CoA, to yield propanoyl-CoA and oxaloacetate.  
 In addition to these reactions, biotin is also known to be associated with additional 
enzymes:  
i. Biotinidase (earlier called biocytinase), a hydrolase that releases biotin from 
oligopeptides for reuse (72, 118). In the normal breakdown of cellular proteins, 
these biotin-containing enzymes are degraded to biocytin (ε-N-biotinyl-L-lysine) 
or short oligopeptides containing biotin-linked lysine residues (72). In humans, 
biotinidase deficiency can cause late onset carboxylase deficiencies (118).  
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ii. Biotin binding proteins such as avidin from egg-white have been isolated (99). 
Together with Paul György's group, Snell showed that avidin was the "toxic" 
protein in raw egg-white previously known to produce egg-white injury (biotin 
deficiency) in animals (45, 53). Streptavidin was isolated from the gram-positive 
bacterium, Streptomyces avidinii (24). These two biotin binding proteins have the 
strongest non-covalent binding affinity to biotin with a disassociation constant 
Kd~10-15 (50) and have been extensively used in biochemical assays to isolate and 
study biotin-dependent enzymes.  
1.3 CLASS I AND CLASS II BIOTIN PROTEIN LIGASES 
 The post-translational attachment of biotin to biotin-dependent proteins is carried 
out by biotin protein ligases (BPL). Biotin is attached to these proteins in a two-step 
process (Figure 1.2). First biotin, then ATP and Mg2+ bind to BPL, where it is converted 
to a tightly-bound mixed anhydride called biotinoyl-5'-AMP. The biotin moiety of the 
activated intermediate is then transferred to the ε-amino group of a specific lysine residue 
of the acceptor protein (biotin carboxyl carrier protein, BCCP) (Figure 1.2).  There are 
two variants of BPLs; class I BPLs are monofunctional enzymes that lack the N-terminal 
helix-turn-helix motif, while class II BPLs are bifunctional enzymes that have a N-
terminal winged helix-turn-helix domain involved in DNA-binding (Figure 1.3A and 
1.3B). Comparative genomic and phylogenetic analyses have shown that the presence of 
a N-terminal domain in BPL is correlated with the presence of putative BPL-binding sites 
within biotin operon promoters. Moreover, these predicted binding sites are well 
conversed among various bacterial and archaeal genomes (92). Mechanistically, 
biotinylating enzymes belong to the family of adenylating enzymes, such as the amino 
acyl-tRNA synthetases (94) and lipoate protein ligase enzymes (48) (Figure 1.4B). Both 
biotin and lipoic acids are covalently attached to proteins via an amide linkage between 
the coenzyme and a specific lysine residue. Moreover, both these members use an 
adenylated intermediate in their reactions. Structural comparison of these enzymes 
suggests that evolution of these families involved structural divergence followed by 
functional convergence (119). 
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 The Class I BPLs have two-domain structures that comprise the minimum 
catalytic unit essential for biotinoyl-5'-AMP synthesis (87, 120). Class I BPLs lack a 
DNA-binding domain at the N-terminal domain, consistent with the biotin metabolism of 
these organisms. Both yeast and humans require exogenous sources of biotin and 
therefore the BPLs lack (and have no need for) repressor function. The E. coli BPL 
(EcBirA/BirA) is the most widely studied BPL from the Class II BPLs. Crystal structures 
show that EcBirA has three distinct domains: an N-terminal domain that consists of the 
winged helix-turn-helix motif involved in DNA-binding, a central domain that contains 
the catalytic subunit of the enzyme, and lastly the C-terminal domain that has been shown 
to be involved in catalytic function and substrate binding. It is important to note that the 
N-terminal domain is also critical for the affinity of the catalytic domain for both biotin 
and biotinoyl-5'-AMP (120). To date there are three available crystal structures of BirA; 
the apo form, the biotin-bound form and a form bound to biotinol-5'-AMP (a biotinoyl-5'-
AMP analogue) (113, 117, 119). The BPLs from Bacillus subtilis, Pseudomonas 
aeruginosa, Methanosarcina barkeri all have an N-terminal domain suggesting a role in 
regulation, whereas Mycobacterium tuberculosis (MtBPL), Pyrococcus horikoshii OT3 
(PhBPL), Saccharomyces cerevisiae (Bpl1), and the mammalian BPL also known as 
holocarboxylase synthetase (HCS) are examples of BPL class I enzymes lacking the N-
terminal regulatory domain (75). However other organisms, like Agrobacterium 
tumefaciens, Lactococcus lactis, Halobacterium sp., Pyrococcus furiosus have genes for 
two BPL paralogs, one with and one without the N-terminal regulatory domain (92). In 
humans, two isoforms of BPLs exist and they differ at the N-terminus by 57 amino acids 
due to mRNA splicing (57). Based on steady-state analysis, both isoforms have similar 
kinetic properties for the first half of the ligation reaction, but the full-length BPL 
associates with the minimal biotin acceptor protein at a rate twice as fast compared to the 
truncated isoform (57). Therefore, the N-terminal region appears to be involved in biotin 
acceptor substrate recognition. However, the biological significance of distinct BPL 
forms in the same organism is still unclear.  
 The eukaryotic BPLs are almost twice the size of the bacterial and archeal 
proteins, yet their C-termini are quite similar to the C-termini of the Class II BPL 
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proteins. The role of the N-terminal half of the eukaryotic BPLs is still unknown. Based 
on its small size the Arabidopsis thaliana BPL is similar to the smaller bacterial BPL, but 
its NTD is involved in organelle targeting. However, the strong amino acid conservation 
within the catalytic subunit of the glycine-rich motif  (GXGXXG) associated with 
binding to biotin and Bio-5ʹ′-AMP (64, 119) together with the close proximity between 
Bio-5ʹ′-AMP binding and the biotin binding suggests a strong functional conservation 
between the bacteria, archaea and eukaryotic BPL (Figure 1.4A). In addition to key 
structural differences, these BPLs also exist in different oligomeric states. MtBPL is 
monomeric in its apo and holo forms (91) (Figure 1.3D), whereas PhBPL exists in a 
dimeric form (8) (Figure 1.3C). In fact, crystal structures of PhBPL-PhBCCP have 
revealed that association results in a 2:2 heterotetramer complex (9). Finally, the EcBirA 
is monomeric when it carries out the synthesis of the biotinoyl-5'-AMP (Figure 1.3E) and 
interacts with the EcBCCP. On the other hand, the holo-EcBirA forms a dimer to bind the 
palindromic bio operator via its DNA-binding domain and to repress biotin synthesis 
(Figure 1.3F). Unfortunately, in the case of EcBPL-EcBCCP the structural details of the 
second step of biotinylation reaction are not completely resolved.  
1.4 THE ESCHERICHIA COLI BIOTIN OPERON 
 In E. coli biotin synthesis is dependent on the enzymes encoded by six genes, 
bioA, bioB, bioF, bioC, bioD and bioH. The five structural genes bioABFCD constitute 
the biotin (bio) operon in E. coli (Figure 1.5). The bioH gene is located far away on the 
genome and is involved in the early part of the biotin synthesis pathway (3, 66). The bio 
operon is arranged in a bidirectional orientation with the two promoters located “back to 
back.” The bioA gene is transcribed from the left (l) and the bioBFCD comprises the right 
(r) half of the operon. Divergent transcription of this gene cluster was first visualized by 
Das Gupta et al. (39) using electron microscopic visualization of RNA polymerase 
holoenzyme binding to a DNA fragment containing the bio operon. They demonstrated 
that transcription of the bio operon was regulated by biotin using hybridization of pulse 
labeled bio-specific messenger RNA of bio-transducing phage λbiot124 in E. coli cells 
grown in biotin-free media and compared to those grown in biotin-supplemented 
medium. Two transcripts originate at and are regulated by two separate promoters located 
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between bioA and bioB (61, 90). Complementation studies by Cleary et al. (33) showed 
that bioBFCD constitute an operon transcribed rightward from a promoter located 
between bioA and bioB, transcription of which is repressible by biotin. Support for this 
regulatory scheme subsequently came from investigations by Eisenberg (46) in which he 
demonstrated that the synthesis of both the 7,8-diaminopelargonic acid aminotransferase 
enzyme (encoded on the l strand) and the dethiobiotin synthetase enzyme (encoded on the 
r strand) are repressed by biotin and α-dehydrobiotin (which functions as a biotin anti-
metabolite). He also observed that the other biotin analogues, homobiotin and α-
methylbiotin were not as effective in repression as biotin and α-dehydrobiotin. The 
regulatory region was sequenced by Otsuka and Abelson (82) and showed that the 
promoters were “face-to-face”, and that the operator and the promoter region overlapped. 
They found a large imperfect palindrome that partially overlaps both promoters. Several 
aspects of the divergently transcribed bio operon proposed by Otsuka were confirmed by 
the genetic characterizations and DNA sequence analyses of Barker et al. (13). They used 
bio-lac fusion strains of E. coli to isolate operator-constitutive mutations within the bio 
operon and found that a GC-AT transition at +15 and a symmetrical change located 
within the palindrome at -15 both resulted in constitutive promoters. Taken together, 
these results showed that single point mutations could affect function of both promoters 
indicating that a single operator overlaps the promoters, as postulated by Otsuka and 
Abelson (82). 
1.5 BIOTIN REPRESSION AND BIOTIN PROTEIN LIGASE ACTIVITY ARE 
ENCODED BY THE SAME GENE, birA 
 The bio system, like the arg, ara, λ phage promoter (λpR) and mal systems, is a 
divergently transcribed operon, in that the two transcriptional units are coordinately 
regulated by a single region. In the case of ara and λpR operons the rationale for divergent 
transcription is auto-regulation. This is not the case for the bio genes, in which the 
transcription of the repressor is independent of the expression of the remaining bio 
operon. Pai and Lichstein (1962) were the first to provide early evidence that there was a 
coordinated regulation of the biotin biosynthesis by repression rather than feedback 
inhibition (85). They observed that increased biotin supplementation of the growth 
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medium decreased biotin synthesis. In 1972 Campbell et al. (21) isolated a recessive 
mutant (bir) of E. coli mapping at minute 88 of the genome map that required a high 
concentration of biotin for growth even in a biotin prototrophic strain. This mutant allele 
(later named birA1) caused a defect in biotin uptake and the depression of the biotin 
synthesis (except at very high biotin concentrations). Later that year, Pai (1974) reported 
the isolation of an E. coli mutant strain (bioR) that excreted high levels of biotin and also 
mapped at minute 88 (84). In the bioR strain the biotin pathway was depressed at even 
the highest biotin supplementation and therefore the reduced rate of biotin uptake in this 
mutant was a consequence of biotin overproduction. However unlike the birA strain, the 
bioR strain had a normal biotin requirement (83). Pai proposed that the reason for the de-
repression of the biotin operon in the bioR strain could be caused either by an altered 
repressor protein or by an alteration in co-repressor synthesis. He speculated that, based 
on the difference in the growth pattern and the regulation by the bir and bioR, the 
mutations were not identical. However, based on the location (near the bfe locus) and the 
similarity in several phenotypic characters shared between the bioR and the bir mutant 
strains, the genes affected might be the same. At this time when the biotin pathway and 
its intricacies were being discovered and understood, methods such as messenger 
hybridization and enzyme assays laid the early foundation to deconvolute the different 
enzymes involved in the pathway. But to answer the question whether the bir mutation 
constituted an alteration of the bioR gene, or defined a nearby gene, or was in fact a 
single genetic change, more direct methods were needed. For this, Barker and Campbell 
(12) developed fusion strains, such that expression of the lacZ was under biotin control in 
these strains, namely, BM2661 (a bioF::lacZY fusion) and BM1161 (a bioA::lacZY 
fusion) that were constructed by the Casadaban method (22, 23). It provided a direct and 
efficient method for selecting auxotrophic mutations in a given nonessential pathway. 
Moreover, the β-galactosidase assays are simple yet highly sensitive and quantitative 
methods useful in characterizing gene function. By use of these fusions, several different 
classes of mutants were isolated and characterized (20); these were broadly categorized 
into bioR mutants (mutants having an altered biotin-specific repressor, but retaining the 
ability to utilize exogenous biotin) and birA mutants (mutants that were defective in 
biotin utilization and repressed only by abnormally high concentrations of exogenous 
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biotin). Even amongst the mutants categorized as bioR or birA mutants there was a wide 
range of phenotypes in biotin uptake, biotin requirements and BPL activity within each of 
these groups. Later, Barker and Campbell (10, 11) used complementation and 
biochemical assays to demonstrate that certain mutations belonging to the bioR group 
were also defective in synthetase activity. This work led to the re-designation of the bioR 
mutations as birA. Therefore mutations/lesions in the birA locus resulted in (to varying 
degrees) both derepression of the biotin operon and elevated biotin requirements for 
growth along with decreases in biotin uptake and defective biotin protein ligase activity.   
 Although the evidence for a bi-functional protein from these laboratories was 
compelling, the ultimate proof required purification of the repressor protein to 
homogeneity. Eisenberg et al. (1982) showed that their most purified repressor 
preparations had all three activities, biotin binding, biotinoyl-5ʹ′-AMP synthesis and in 
vitro repression (47). A single 34,000-dalton protein having a pI of 7.2 possessed both the 
regulatory and enzymatic activities and the common link in all of these reactions was the 
formation of BirA-biotinoyl-5ʹ′-AMP complex. The purification of the biotin-repressor 
protein proved the model proposed by Barker and Campbell that birA encodes a single 
protein that has both biotin protein ligase and bio operon transcription repression 
activities. When the coding region for birA was finally sequenced (55), the mutations that 
affected biotin requirement and ligase function of the enzyme were located within the 
central region of the protein, whereas those affecting the repressor function of the protein 
mapped to the N-terminal region of the protein, which contained the helix-turn-helix 
motif typically found in DNA-binding proteins (19). 
 BirA exists in three distinct conformational states, depending on which of the 
ligands is bound, namely, apoBirA, BirA-biotin or BirA-bio-5ʹ′-AMP complex (122). 
Substrate binding to BirA causes large structural changes because attempts to make BirA-
biotin or BirA-bio-5ʹ′-AMP complexes resulted in destruction of the BirA crystals (117). 
The three-dimensional crystal structure reveals an asymmetric protein with three distinct 
domains (117). As predicted from the genetic studies, there is a central catalytic domain 
and an N-terminal DNA binding domain. The C-terminal domain structurally resembles 
the SH3 domain of the tyrosine kinases and is believed to interact with apo-acceptor 
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protein and to bind ATP (80). The catalytic site is located on a solvent-exposed face of 
the central domain. The GRGRRG motif is found within the central domain and is part of 
the biotin-binding loop. Based on kinetic and thermodynamics data, this motif is involved 
in biotin and co-repressor binding. Mutations in this motif have also been shown to affect 
DNA binding and dimerization (64). Biotin binding to BirA induces a disorder-to-order 
transition that is a prerequisite to dimerization (120). Kinetic measurements of the 
binding of biotin and ATP to BirA indicate ordered addition, with biotin binding first 
(122). Only after biotin binds and the biotin-binding loop gets ordered, the adenylate 
binding site forms a well-defined structure to cover the co-repressor (119). This is 
consistent with the fact that ATP binds only very weakly to BirA in the absence of biotin 
(122). The co-repressor, Bio-5ʹ′-AMP binds BirA with significantly higher affinity than 
biotin and is a 1000-fold more effective than biotin in forming repressor-DNA complex 
(89, 122). The binding of the Bio-5ʹ′-AMP leads to improved packing at the BirA dimer 
interface, which in turn increases the stability of the BirA dimer (119).  
1.6 REGULATION OF BIOTIN BIOSYNTHESIS IN ESCHERICHIA COLI 
 As mentioned above, in E. coli the expression of the biotin synthesis (bio) operon 
is controlled by BirA, a regulator that is not only the repressor that regulates the bio 
operon expression by DNA binding, but is also the enzyme that covalently attaches biotin 
to its cognate acceptor protein. Therefore, the signal recognition and the regulatory output 
reside in the same polypeptide. The transition of BirA from a BPL to a repressor is 
dependent on the binding of Bio-5ʹ′-AMP accompanied by a conformational change that 
results in dimerization of the protein and subsequent binding to the bio operator (105). 
The maximal rate of E. coli bio operon transcription (derepression) (Figure 1.5A) occurs 
when the biotin supply is severely limited. Therefore, increased bio operon transcription 
is triggered either by the inhibition of co-repressor synthesis (Bio-5ʹ′-AMP) by 
intracellular biotin limitation or by the increase in the level of Bio-5ʹ′-AMP consumption 
due to high levels of apo-acceptor protein (1, 36). These two conditions act by a common 
mechanism in that both decrease the level of BirA-Bio-5ʹ′-AMP complex available to 
dimerize and bind the bio operator. Therefore, the degree of repression of bio operon 
transcription can be readily understood within the Campbell-Eisenberg model as a 
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competition between the unmodified acceptor protein and the BirA protein for the 
biotinoyl-5ʹ′-AMP (36). When the biotinoyl-5ʹ′-AMP synthesized by BirA protein remains 
bound to the protein, it results in the activation of the BirA protein to allow repression of 
the biotin operon, therefore over-expression of BirA results in super-repression (10, 89, 
121) (Figure 1.5B).  However, if sufficient apo-acceptor protein is available, the biotin 
moiety is transferred to form the biotinylated protein. Therefore the absence of the Bio-
5ʹ′-AMP causes the BirA protein to lose the ability to specifically bind the biotin operator 
sequence. Thus, overexpression of an apoprotein substrate leads to depression of the bio 
operon through consumption of the Bio-5ʹ′-AMP in biotinylation of the acceptor protein 
(36). Overall, the regulatory activity by BirA is dependent on the intracellular level of the 
unmodified protein, as well as the intracellular biotin concentration. Regulation by apo-
protein levels makes excellent metabolic sense in that biotin functions in CO2 transfer 
only when attached to its cognate proteins (28). 
1.7 BIOTINYLATION 
1.7.1 Interaction of Biotin Protein Ligases with the Protein Substrate. 
 Biotin is an essential coenzyme because it performs catalytic roles in critical 
metabolic pathways. Biotin is covalently bound to proteins via amide linkages between 
the coenzyme carboxyl group and a specific lysine residue that is catalyzed by a BPL 
(Figure 1.2). In most of the biotin containing enzymes the biotin carrier domain is 
situated at the carboxyl terminus of the peptide chain, moreover this region is highly 
resistant to proteolytic cleavage (34). Based on available sequence data the biotin 
attachment domains of biotinylated proteins share a high degree of structural similarity. 
Specifically, the biotinylated lysine residue is located about 35 residues from the C-
terminus and is found within a highly conserved AMKM tetrapeptide (34, 37, 96). 
Additional studies into the efficiency of biotinylation of truncated forms of biotin 
domains have shown that a minimum of 75-80 residues is necessary to specify 
biotinylation (34, 76). The BPLs have species promiscuity and a given BPL can 
biotinylate foreign acceptor proteins, albeit often to a lesser degree than their cognate 
acceptor proteins.  
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 BPLs from a variety of different organisms have been studied, which have 
provided insight into the catalytic mechanism. The coding sequences of the BPLs and 
biotin carrier domains of biotin-containing enzymes highlight a strong conservation both 
between the ligase structure and the functional interaction between enzyme and their 
cognate protein substrate. This evolutionary conservation is evident amongst all three 
kingdoms of life. In fact, several BPLs (yeast, humans and plants) were identified by 
genetic complementation of the E. coli birA1 strain, thereby illustrating the strong 
conservation of the functional interaction between the enzyme and protein substrate.  
Even though several foreign biotin domains have been demonstrated to be biotinylated in 
E. coli, there is variation in the level of efficiency between these biotinylated substrates. 
This rate of biotinylation of cognate and non-cognate BCCP substrates by the BPL is 
dictated by the enzyme-substrate specificity (57). For example, the PhBPL is quite 
promiscuous and can biotinylate heterologous biotin domains from different organisms, 
whereas the Homo sapiens BPL (HsBPL) shows the most stringency in biotinylation (56, 
58).  The mammalian BPL, holocarboxylase synthetase (HCS) has five biotin-dependent 
carboxylases as substrates and regulates the distribution of biotin amongst its 
carboxylases by displaying a higher affinity for the mitochondrial carboxylases vs. the 
acetyl-CoA carboxylase found within the cytoplasm (58). This is hypothesized to be 
determined by the substrate specificity of the BPL for the different carboxylases (58).  
1.7.2 Biotinylated Protein Fusions. 
 Enzymatic biotinylation has proven to be a powerful biochemical tool that has led 
to the advent of several commercially available biotinylation kits that enable uniform and 
efficient biotin labeling of proteins and peptides. The small size of biotin makes it 
excellent for protein labeling because it does not interfere with the function of the 
protein. Secondly, the valerate side chain found in biotin can be easily derivatized 
without affecting its ability to bind to avidin/streptavidin. In vivo biotinylation coupled 
with recombinant DNA technology proved to be a powerful tool to tag proteins of interest 
with the biotin-accepting domain (37). These biotin domains can be either placed as an 
in-frame fusion within the protein or at the N-or the C-terminus of the protein. Similarly, 
small peptides substrates for BirA have been identified from peptide libraries by Schatz 
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(1993) (97) and can also be fused to a wide variety of proteins. These sequences of 14 to 
30 resides are efficiently biotinylated either in vitro or in vivo. Surprisingly, these 
peptides have very little similarity to the known biotinylated sequences of BCCP 
subunits. These peptides have proven useful in understanding the structure-function 
mechanism that drives substrate specificity by BPL (16, 101). Uses of biotinylation tags 
have proven to be highly efficient in protein purification and detection. Coupled with the 
high affinity between biotin and avidin/streptavidin (Kd = 10-15 M to 10-14 M), fusion 
proteins can be readily purified from columns of immobilized avidin or streptavidin, in 
denatured state, or in native state using low affinity forms of these biotin binding 
proteins, making purification of these fusion proteins very specific and efficient. In vivo 
biotinylation has also been used as a sensitive reporter of protein sorting in both 
prokaryotes and eukaryotes. It has been used as a localization tag and to monitor how 
proteins are distributed within the cell. Therefore biotinylated fusion proteins can be used 
in many research applications, like enzyme-linked immunosorbent assay (ELISA), 
immunoprecipitation (IP), western blot analysis and other methods of affinity 
purification. In vivo biotinylation of fusion protein using heterologously expressed E. coli 
has also been used both in prokaryotes and eukaryotes. In cases where only modest 
fusion protein expression is desired, the level of biotin-ligase expressed from the 
chromosomal level in the host cell is sufficient to give the biotinylated protein. However, 
where a high level of expression of biotinylated fusion protein is required, the co-
expression of E. coli biotin ligase can be used (37). 
1.8 AIMS AND SCOPES OF THIS THESIS 
The subject of this thesis, the BPL and the bio operon repressor BirA of E. coli, 
provides a parsimonious example of the dichotomy between enzymatic and regulatory 
activities. In the case of birA, since the repressor function and the enzymatic function are 
coupled, BirA is able to regulate the synthesis and the utilization of the biotin within the 
cell. Most of the biotin found within the cell is protein-bound (84), thus the synthesis of 
biotin from the bio operon is closely regulated by its consumption in protein 
modification. In fact very little biotin is excreted (<0.05 nM) and there is very little 
intracellular biotin (10 nmol/L) (89). The overall regulation of the biotin operon is well-
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supported by in vivo experiments that provide key insight into the intricate mechanism 
that coordinates the regulatory and enzymatic function of BirA. To date, several crystal 
structures of BirA protein have been solved which have led to a better understanding of 
the structure-function relationships of the DNA-binding and enzymatic domains of BirA. 
BirA is the best-studied member of Type II BPLs, those having an N-terminal domain 
that contains a winged helix-turn-helix (wHTH) involved in DNA binding. In the extant 
crystal structures the N-terminal domain is well separated from the other domains of the 
protein (113, 117, 119). Hence, it would seem straightforward to delete the N-terminal 
domain and thereby convert the protein from a class II ligase to a class I ligase.  
However, the first BirA N-terminal deletion mutant unexpectedly had severely 
compromised enzymatic activity in addition to being unable to bind DNA (120). The 
truncated ligase bound both biotin and the intermediate of the ligation reaction, Bio-5ʹ′-
AMP, extremely poorly. The data from the N-terminal truncation mutant and from other 
mutants strongly suggests that this small protein coordinates its regulatory and enzymatic 
functions by communication between the ligase active site and the seemingly distant N-
terminal domain. The mechanism of this communication remains unknown. Also, in the 
absence of a BirA-corepressor-bioO complex structure, it has been difficult to predict the 
exact mode of interaction of BirA with DNA. The present crystal structures give no 
information as to the mode of interaction between the DNA binding domain with the 
catalytic and the carboxy-terminal domains. Therefore various studies were initiated, 
aimed at better understanding the regulation of the biotin operon and the biotinylation 
functions of BirA. 
 Chapter 2 of this thesis describes the isolation and characterization of 
superrepressor mutant strains of BirA (25). These mutants would repress the biotin 
operon transcription in vivo at biotin concentrations well below those needed for 
repression by wild-type BirA. Such mutants have been difficult to isolate in the past, 
since most BirA superrepressor mutants are lethal because the DNA-bound mutant of 
BirA would be unable to perform the essential biotinylation activity for fatty acid 
synthesis. To avoid lethality I carried out the selection-screen in the presence of a 
plasmid-borne copy of the biotin protein ligase from Saccharomyces cerevisiae (Bpl1). 
Bpl1 provides full ligation function but does not effect BirA regulation. I isolated mutant 
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strains having the superrepressor phenotype by a combined selection-screening approach 
and resolved multiple mutations to give several birA superrepressor alleles, each having a 
single mutation, all of which showed repression dominant over that of the wild-type 
allele. The properties of the superrepressor mutants further extend and support the model 
that the repressor function and ligase activity of BirA are closely intertwined. 
 Chapter 3 investigates the structural and functional role of the wing of the wHTH 
motif in the enzymatic activity, as well as in the transcriptional regulatory function of 
BirA (26). The structural and sequence integrity of the wing domain was found to be 
essential for both the biotinylation and regulatory activities of BirA. Additionally, the 
wing of the DNA-binding domain was shown to coordinate the two functions of BirA. 
This study is the first example of a wing domain having a role in an enzymatic activity. 
 Finally, Chapter 4 summarizes the results from the preceding chapters and 
discusses the implications for future work. 
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1.9 TABLES AND FIGURES 
 
 
Figure 1.1. Acetyl-CoA carboxylase reaction. In E. coli the Acetyl-CoA carboxylase 
(ACC) carries out the synthesis of malonyl-CoA from acetyl-CoA and bicarbonate. 
Malonyl-CoA is the key precursor of fatty acid synthesis. In most bacteria ACC is multi-
subunit and is composed of three functional entities: biotin carboxylase (BC, encoded by 
accC), biotin carboxyl carrier protein (BCCP; encoded by accB), and carboxyltransferase 
(CT; encoded by accA and accD). AccB-AccC complex consists of an AccC dimer plus 
four copies of AccB. This complex binds to an α2β2 heterotetramer of the AccA and 
AccD subunits to form active ACC. Malonyl–CoA synthesis is carried out in two steps. 
The first step of the ACC reaction is the carboxylation of biotin bound to BCCP by the 
biotin carboxylase (BC). In the second partial reaction, the carbonyl group is transferred 
from the biotin moiety to acetyl-CoA by the carboxyltransferase (CT) subunit, to give 
malonyl-CoA. Modified from reference (1).  
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Figure 1.2. The biotin protein ligase reaction. Biotinylation is catalyzed through a two-
step reaction where biotin is first activated to biotinoyl-5ʹ′-AMP in an ATP dependent 
manner. In the second step, the biotin protein ligase catalysis the post-translational 
formation of the amide linkage between the carboxyl group of biotin and the amino group 
of a specific lysine reside of apo-acceptor protein to give the biotinylated protein. 
Modified from reference (1). 
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Figure 1.3. A schematic illustration of the biotin protein ligases from Class I and 
Class II.  Panels A and B illustrate the classification of BPLs. The catalytic core and the 
carboxyl terminus are conserved between the two BPL. The class II BPLs contain a 
winged helix-turn-helix motif within the N-terminal domain that is involved in DNA-
binding. In Panel C and Panel D are the crystal structures of class I BPLs, PhBPL and 
MtBPL, respectively.  The PhBPL can exist as a dimer in all the three forms, apo, biotin 
liganded and bio-5′AMP liganded (8), whereas the MtBPL is monomeric in all three 
forms (91).  The EcBirA is the most well studied BPL from class II. EcBirA is 
monomeric in apo and biotin-liganded form (Panel E) but a dimer when associated with 
bio-5′AMP (Panel F). The models were made using the program Chimera (86) and the 
PDB files used were: BirA, 1HXD; BirA, 2EWN; PhBPL, 2DTI; MtBPL 2CGH. The N- 
and C-termini are denoted by N and C, respectively, wHTH denotes winged helix-turn-
helix domain, CTD denotes C-terminal domain.
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Figure 1.4. The minimum evolution analysis of alignments of BPLs from class I and 
II (Panel A), and the catalytic domains from BPLs and lipoylating enzymes (Panel 
B). The trees were made using software Phylogeny.fr (42, 43) and the bootstrap 
percentage values are shown for each branch and panel. The scale represents a 60% for 
Panel A and 70 % difference for Panel B in compared residues per length. Panel A: 
Analysis of selected biotin protein ligases identified in the UniProt Consortium as 
members of the “Biotin protein ligase family”. These BPLs were specifically selected to 
generate the tree because these members have been manually reviewed for their function 
in UniProtKB/Swiss-Prot. Panel B: Analysis of selected catalytic domains from PF03099 
in which the structurally related lipoyl ligases (LplA and LipB) were used as the out-
group. In each case the sequence number corresponds to the catalytic region that was 
used to generate the alignment. 
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Figure 1.5. The E. coli biotin operon regulation. Panels A and B show the general 
model of bio operon regulation. The ovals denote BirA, tailed circles are AccB, red 
circles represent biotin, and red circles with green stars denote biotinoyl-adenylate (Bio-
5ʹ′-AMP). Panel A shows the transcriptionally derepressed state engendered by biotin 
limitation whereas panel B shows the repression of bio operon transcription in the 
presence of excess biotin or absence of apo-acceptor protein. birA encodes BirA, the 
EcBPL, the gene accB encodes BCCP, the biotinylated subunit of E. coli acetyl-CoA 
carboxylase and the bioABCDF genes encode enzymes of biotin biosynthesis. The figure 
is modified from reference (35). 
ATP
bioA
bioO
bioBFCD
birA accB
Biotinylated-BCCP
ATP
bioA
bioO
bioBFCD
birA accB
Biotinylated-BCCP
Derepression
Repression
A.
B.
	   20	  
CHAPTER 2 
 
ALTERED REGULATION OF ESCHERICHIA COLI BIOTIN BIOSYNTHESIS 
IN BIRA SUPERREPRESSOR MUTANT STRAINS 
2.1 INTRODUCTION 
 The bacterial cell is an intricate machine in which processes are fine-tuned to allow 
the bacterium to adjust and successfully sustain growth in ever-changing environments.  
In many cases specific protein-DNA interactions play vital roles in coordination of these 
processes. The Escherichia coli BirA repressor is a simple but unusually sophisticated 
regulator that represses biotin operon transcription. The sophistication arises because 
BirA is also an enzyme, it catalyzes the covalent attachment of biotin to its cognate, 
metabolically essential acceptor protein. Indeed, regulation of the E. coli biotin operon is 
probably the best understood example of transcriptional regulation by an enzyme 
unrelated to nucleic acid metabolism. Superficially, the system resembles the classical 
TrpR regulation of the E. coli tryptophan operon in which the TrpR repressor protein 
binds to the trpEDCBA operator only when bound to the co-repressor, tryptophan.  
However, in bio operon regulation, the repressor is also the sole E. coli biotin protein 
ligase and thus is an essential protein and the co-repressor is not biotin, but biotinoyl-
adenylate (biotinoyl-5ʹ′-AMP), the product of the first half-reaction of the ligase reaction 
(Figure 2.1A). It is these novel features that give this regulatory system its unusually 
subtle properties. 
 The overall model of biotin operon regulation is well supported by in vivo 
experiments (1, 10-12, 36, 101) in which a collection of BirA mutants isolated by Barker 
and Campbell (12) provided key insights. However, our knowledge of the molecular 
mechanism whereby BirA accomplishes its diverse tasks is incomplete. The major gap is 
an understanding of the conformation adopted by BirA when it is bound to the bio 
operator. It occurred to us that a new class of birA mutants might help provide the needed 
structural information. Although Barker and Campbell (12) isolated birA mutants 
defective in repression or defective in both repression and ligase activity, no birA 
superrepressor mutant strains have been reported. This and other work indicated that 
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repressor function and ligase activity are closely intertwined. In order to further test and 
extend the model I have isolated and characterized the first examples of a new class of 
BirA mutants. These are superrepressor mutants that remain repressed under conditions 
that result in derepression of the wild-type strain. In the classical LacI lactose utilization 
repressor system, super-repression can be due to mutant repressors that no longer bind 
inducer or that bind inducer, but fail to undergo the conformational transitions required to 
release the operator (116). In the case of the E. coli tryptophan operon super-repression 
results from mutant TrpR repressors that bind the trp operator in the absence of 
tryptophan (68). Given the greater complexity of the bifunctional BirA, a greater 
diversity of superrepressor mutant classes might be anticipated and unlike the cases of 
Lac and Trp, some classes might be lethal mutations due to loss of the essential ligase 
activity. Given this possibility I designed a successful selection-screening approach using 
chromosomal transcriptional fusion constructs driven by the divergent bio operon 
promoters to isolate birA superrepressor mutant strains under conditions that ensured 
survival of lethal birA mutations. I report the in vivo and some in vitro properties of some 
members of this new birA mutant class. 
2.2 MATERIALS AND METHODS 
Chemicals and culture media. All bacterial strains were derivatives of E. coli K-12 
(Table 2.1).  The medium used in the physiological experiments was LB as the rich 
medium whereas the defined medium was M9 salts supplemented with 0.4% glucose (or 
another carbon source as stated) and 0.1% Vitamin-Free Casamino Acids (Difco). The 
cultures were grown at 37°C with vigorous aeration and growth was measured by the 
absorbance at 600 nm using a Beckman DU600 spectrophotometer unless otherwise 
indicated. Glycerol was used instead of glucose for growth of strains containing the 
pBAD33-derived plasmid, pVC17. Oligonucleotides (Table 2.2) were synthesized by 
Integrated DNA Technologies. PCR amplification was performed using Taq polymerase 
(New England Biolabs) and Pfu polymerase (Stratagene) according to the manufacture’s 
specifications. DNA constructs were sequenced either by the Roy J. Carver 
Biotechnology Center of the University of Illinois or by ACGT, Inc. All reagents and 
biochemicals were obtained from Sigma-Aldrich unless otherwise noted and New 
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England Biolabs supplied restriction enzymes. American Radiolabeled Chemicals 
provided [α-32P] ATP (6000 Ci mmol-1) whereas Perkin Elmer provided [γ-32P] ATP 
(3000 Ci mmol-1) and d-[8,9-3H(N)]biotin (32.6 Ci mmol-1). The concentrations of 
antibiotics used in this study were as follows (in µg/mL): sodium ampicillin (Amp), 100; 
kanamycin sulfate (Km), 50; chloramphenicol (Cml), 25, tetracycline HCl (Tet) 12 and 
spectinomycin sulfate (Spec) 50. The 15:1 mixture of ticarcillin disodium salt and 
potassium clavulanate (Research Products International) was used at 25 µg/mL, unless 
otherwise stated. 
Bacterial strain constructions. Strain VC150 was constructed by the Datsenko and 
Wanner method (40). The chromosomal copy of the birA gene of strain VC146 was 
replaced with a kanamycin resistance cassette by transformation with the PCR product 
obtained using primers VCA10 and VCA11 and pKD4 as template. The replacement was 
confirmed using primers VCA12 and VCA13 plus the internal primers K2 and KT, 
respectively. The insertion was then transduced with phage P1vir into strain VC125, a 
derivative of strain MG1655 carrying plasmid pCY255 (38) to give strain VC156. Other 
DNA manipulations were preformed by standard procedures (95). The antibiotic 
resistance was removed from strain VC156 using the Flp recombinase encoded by the 
temperature-sensitive plasmid pSRK20. Strain VC205 was derived from strain VC156 by 
phage P1 transduction of ΔlacZY::cat insertion of JT33 followed by selection on LB 
media supplemented with ampicillin and chloramphenicol. Strain VC203 was constructed 
by homologous recombination catalyzed by the phage l red system (40). The lacA gene 
of in the chromosomal φ(bioF::lacZYA)501 fusion of strain CY481(36) was replaced 
with a kanamycin resistance cassette by transformation with the PCR product obtained 
using primers VCA57 and VCA58. The orientation of the construct was then validated by 
colony PCR with primers VCA59 and VCA60 together with the internal primers C1 and 
C2. Strain VC212 was constructed by phage P1 transduction of the bioF::lacZY-km 
fusion of strain VC203 into strain VC205 with selection on MacConkey medium 
supplemented with chloramphenicol, ampicillin and kanamycin. The kanamycin and 
chloramphenicol antibiotic resistance cassettes were then removed as described above to 
give strain VC218. Strain VC218 was transformed with plasmid pSRK40 with selection 
for resistance to both spectinomycin and ampicillin to give VC230. Strain VC230 was 
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then transformed with the PCR product obtained using primers VCA20 and VCA21 with 
pKD3 as template followed by selection for chloramphenicol resistance. Homologous 
recombination generated a construct in which the cat gene replaced bioA. Transformants 
were selected on plates of MacConkey medium supplemented with 12.5 µg/mL 
chloramphenicol and tested by colony PCR for insert orientation using primers VCA71 
and VCA72 together with the internal primers C1 and C2 to give strain VC235. Strain 
VC233, a derivative of strain JT34 (41), was constructed by phage P1 transduction of the 
strain VC203 bioF::lacZY construct with selection on MacConkey medium supplemented 
with kanamycin. The antibiotic resistance cassette was then removed as above.  Strain 
VC233 was transformed with plasmid pVC18 to give strain VC537 which was 
transduced with the ΔbirA::km insertion of strain VC156 to give strain VC618.  
 Strain VC776 was constructed by (108) transformation of VC236 with a PCR 
product encoding the cat::sacB cassette (generated with template CS100 (40, 41) and 
primers VCC44 and VCC49. The insert was confirmed using colony PCR with primers 
VCA12 and VCA13 and by its birA phenotype on defined medium plates containing 4 
µM biotin. A P1 lysate of strain VC776 was used to transduce strain VC730 to 
chloramphenicol resistance. The resulting strain was then transformed with a PCR 
product generated with primers VCC50 and VCC51 using plasmids pVC7 and pVC25 as 
templates. The transformants were plated on defined medium plates supplemented with 4 
µM biotin and 5% sucrose. The resulting colonies were then scored on defined medium 
plates supplemented with 4 µM or 4 nM biotin, to test BirA function. The insert was 
amplified using primers VCC52 and VCC53 and sequenced. The positive candidates 
were then transduced with a P1 phage stock grown on the polA12 strain AK25 with 
selection for a closely linked Tn10 insertion to give strains VC801 and VC802. The 
transductants were then scored for the UV sensitive polA12 phenotype at 42°C, the non-
permissive temperature. The UV sensitive candidates were then tested for growth on 
defined media supplemented with 4 nM biotin and 40 µg/mL 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-gal) at 30°C and 42°C.  
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Plasmid constructions. The birA gene was amplified by PCR from MG1655 genomic 
DNA using primers VCA69 and VCA70 which added terminal EcoRI and NcoI sites. 
This product was then directly ligated into the same sites of the cat gene of the medium 
copy number plasmid pACYC184 to give pVC7. Plasmid pVC18, which encodes S. 
cerevisiae Bpl1, was constructed by PCR amplification using pCY255 as the template 
with primers VCA84 and VCA85, which added flanking SmaI and XbaI sites. The SmaI 
plus XbaI digested BPL1 gene was then inserted into plasmid pEAKI cut with the same 
enzymes. The sequence encoding AccB-87, the C-terminal 87-residue biotinylation 
domain of AccB, was amplified from the genomic DNA of MG1655 using primers 
VCB44 and VCB45, which added flanking sites. This product was digested with SacI and 
HindIII and ligated into the same sites of pBAD33C to give pVC17 with AccB-87 
expression under the control of an arabinose-inducible promoter. Plasmid pVC19 
encoding AccB-87 was constructed by PCR amplification using MG1655 genomic DNA 
with primers VCB57 and VCB58, which incorporated flanking NcoI and BamHI sites. 
This product was digested and inserted between the NcoI and BamHI sites of pET16B. 
Mutant enrichment. Random mutagenesis of the birA gene was performed with the 
GeneMorph II random Mutagenesis Kit using primers VCA69 and VCA70 (Table 2.2) 
and plasmid pVC7 as template at concentrations of 100 ng, 50 ng, 5 ng or 1 ng in a total 
reaction volume of 50 µL. The mutagenesis conditions designed to give fairly high-to-
medium mutation frequencies were used because the complex structural transitions 
undergone by BirA argued that multiple mutations might be needed to increase DNA 
binding.  The PCR products of the mutagenesis reactions were then digested with NcoI 
and EcoRI and inserted into pACYC184 digested with the same enzymes. The ligation 
products were then transformed into strain VC235 with selection on LB plates for 
resistance to ampicillin and tetracycline. The transformants were pooled and diluted 
1000-fold in the defined medium supplemented with 3 µg/mL chloramphenicol and 1.6 
nM biotin. The cultures were grown at 37°C with continuous aeration until the optical 
density increased 2-fold. At this time the ticarcillin-clavulanate mixture (Materials and 
Methods) and sodium ampicillin were added to final concentrations of 200 µg/mL and 50 
µg/mL, respectively.  The cultures were then shaken for an additional 2 h until lysis. The 
surviving cells were harvested, washed with defined medium and plated at different 
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dilutions on defined medium plates supplemented with 12 µg/mL tetracycline, 50 µg/mL 
ampicillin, 1.6 nM biotin and 40 µg/mL X-gal.  Following incubation a mixture of white 
and blue colonies was seen. Plasmids were extracted from the white colonies (the 
superrepressor phenotype) digested with HpaI to linearize plasmid pCY255 and 
transformed into strain VC233. The mutant plasmids were then isolated and sequenced to 
identify the mutations that resulted in the observed phenotype. Site-directed mutagenesis 
was carried out using the Stratagene Quick Change II protocol and the primers of Table 
2.1. The template plasmids were digested with DpnI prior to transformation of strain 
DH5α.  
β-Galactosidase assays. The cultures were grown overnight and then diluted 1:100 into 
fresh medium having the same composition and grown to the early to mid log phase 
before assays were performed. β-Galactosidase activity was determined as described by 
Miller (71) following disruption of the cells by sodium dodecyl sulfate-chloroform 
treatment. 
 In vivo complementation. Strain VC618 was transformed with the plasmids pVC20, 
pVC21, pVC22, pVC23, pVC24 or pVC25 and transformants selected for on LB plates 
supplemented with ampicillin and tetracycline at 30°C. The temperature-sensitive 
plasmid, pVC18, was cured from these strains by growth at 42°C on defined media 
supplemented with tetracycline. The loss of the temperature-sensitive plasmid was 
confirmed by ampicillin sensitivity. These strains were then used to carry out growth 
curve analyses in which cultures were grown overnight in defined medium supplemented 
with 1.6 nM biotin and then diluted 1:1000 into fresh medium having the same 
composition supplemented with different concentrations of biotin. Bacterial growth was 
then monitored using a Bioscreen C instrument with a brown filter and the Norden Lab 
Studio Bioscreen C software. The cultures were grown with strong shaking and the 
absorbance at OD600 with recording every 15 min.  
BirA purification. Expression plasmids encoding a C-terminal hexahistidine tagged 
version of one of the BirA proteins was amplified from genomic DNA using primers 
VCB16 and VCB17 which added terminal NcoI and BamHI sites as well as the 
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purification tag. The digested products were ligated into the same sites of plasmid 
pET19b to give plasmid pVC9.  Plasmid VC9 was then digested with NcoI, treated with 
mung bean nuclease to generate blunt ends and ligated to give plasmid pVC10. Plasmid 
pVC10 was used as the template for site-directed mutagenesis to generate single amino 
acid substitutions. The resulting plasmids were introduced into E. coli strain BL21 
(λDE3).  The BirA proteins were expressed in LB medium containing 100 µg/mL 
ampicillin with induction at an optical density of 0.8 at 600 nm by addition of isopropyl-
β-D-thiogalactopyranoside (IPTG) to 1 mM. The protein fraction was subjected to Ni2+ 
affinity chromatography (32) followed by dialysis against 10 mM sodium phosphate 
buffer (pH 7.5) containing 5% glycerol and 0.1 mM dithiothreitol (DTT) and anion 
exchange chromatography using a Vivapure IEX Q Maxi H spin column. The column 
was successively washed with the above buffer except that the phosphate concentrations 
were increased to 50 mM and then 100 mM.  BirA was eluted with the 100 mM buffer 
containing 100 mM NaCl. The elute was dialyzed against storage buffer (10 mM sodium 
phosphate (pH 7.5), 200 mM KCl, 10% glycerol and 0.1 mM DTT) overnight, 
concentrated using Millipore concentrators, flask frozen and stored at -80ºC. For the in 
vitro biotinylation assays the proteins were dialyzed against 50 mM Tris-HCl (pH 7.5), 
200 mM KCl, 5% glycerol and 0.1 mM DTT prior to use.  
Purification of unliganded-BirA proteins. Plasmids encoding C-terminal hexahistidine 
wild-type BirA (pVC10) or mutant BirAs (pVC11 or pVC15) were transformed into E. 
coli strain ER47 together with pVC17, which encoded AccB-87. Cultures were grown 
overnight at 37°C in defined medium supplemented with 0.1% Vitamin Free Casamino 
Acids, 0.4% glycerol, 12.5 µg/mL ticarcillin-clavulanate mixture, 12.5 µg/mL 
chloramphenicol and 1.6 nM biotin and then diluted 20-fold into medium of the same 
composition. The cultures were then grown to an optical density of 0.8 at 600 nm at 37°C 
and expression of BirA and BCCP-87 was induced by addition of 1 mM IPTG and 0.2% 
arabinose. After growth for 16 h at room temperature the cells were harvested by 
centrifugation and treated as described above to isolate BirA protein.  
Purification of AccB-87. Plasmid pVC19 was transformed into strain BL21 (λDE3). The 
strain was grown in LB medium supplemented with ticarcillin-clavulanate 
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density of 0.5 at 600 nm at which point 0.1 mM IPTG was added followed by growth for 
an additional 4 h. The truncated AccB (AccB-87) was purified as previously described 
(30). The fractions containing the pure protein as judged by SDS gel electrophoresis 
followed by Coomassie Blue staining were dialyzed overnight in 50 mM Tris-HCl (pH 
7.5), 200 mM KCl, 5% glycerol and 0.1 mM DTT. The protein was concentrated and 
stored at -80ºC as above. The AccB-87 preparations were validated by mass spectrometry 
(30).  
Gluc-C endoprotease digestion and LC/MS/MS analysis of BCCP-87. Mass 
spectrometric analysis was conducted at the Protein Sciences Facility, Roy J Carver 
Biotechnology Center, University of Illinois, Urbana, IL 61801 using a Thermo LTQ 
Velos ETD pro mass spectrometer. Prior to LC/MS/MS analysis, Glu-C digestion was 
done using Staph Protease-Sequencing Grade at 1:10 (Worthington Biochemical, 
Lakewood, NJ) using a CEM Discover Microwave Reactor (Mathews, NC) for 15 
minutes at 55°C at 50 Watts.  Digested peptides were extracted 3X using 50% acetonitrile 
containing 5% formic acid, pooled and dried using a Speedvac (Thermo Scientific).  The 
dried peptides were suspended in 5% acetonitrile containing 0.1% formic acid and 
applied to LC\MS. 
 HPLC for the Gluc-C digested peptides was performed with a Thermo Dionex 
3000 RSLCnano using Thermo Acclaim PepMap RSLC column (75 µm x 15 cm C-18, 2 
µm, 100Å) and a Thermo Acclaim PepMap 100 Guard column (100 µm x 2 cm, C-18, 5 
µm, 100Å), solvents were water containing 0.1% formic acid (A) and acetonitrile 
containing 0.1% formic acid (B) at a flow rate of 300 nanoliters per minute at 40ͦ C.   
Gradient was from 100% A to 60% B in 60 minutes. The effluent from the UHPLC was 
infused directly into a Thermo LTQ Velos ETD Pro mass spectrometer. Control and data 
acquisition of the mass spectrometer was done using Xcalibur 2.2 under data dependent 
acquisition mode, after an initial full scan, the top five most intense ions were subjected 
to MS/MS fragmentation by collision induced dissociation.  The raw data were processed 
by Mascot Distiller (Matrix Sciences, London, UK) and then by Mascot version 2.4. The 
result was searched against NCBI NR Protein database. 
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Biotinoyl-adenylate synthesis. Protein concentrations were determined using the 
extinction coefficients calculated from the ExPASY Tools website. The assays contained 
100 mM sodium phosphate buffer (pH 7.5), 5 mM (tris (2-carboxyethyl) phosphine), 0.05 
mM MgCl2, 0.01 mM biotin, 0.1 µM  [α-32P] ATP and 1 µM BirA protein. The reactions 
were incubated at 28ºC for 30 min, at which time the reaction was split. To one tube 
AccB-87 was added and incubated for an additional 15 min at 28ºC whereas the other 
half reaction was left untreated.  One microliter of each reaction was subjected to 
cellulose thin layer chromatography on plates containing a fluorescent indicator that were 
developed in isobutyric acid:NH4OH:water (66:1:33) (89). The thin layer chromatograms 
were dried for 10 h and exposed to phosphorimaging plate and visualized using a Fujifilm 
FLA-3000 Phosphor Imager and Fujifilm Image Gauge software (version 3.4 for 
Macintosh).  
Electromobility shift assay (EMSA) of DNA binding affinity. A 112-bp DNA 
substrate containing the bioO operator was PCR amplified with Taq polymerase from 
MG1655 genomic DNA using primers VCB36 and VCB37. The PCR product was 
subjected to electrophoresis on a 5% polyacrylamide gel and extracted from the gel using 
the following protocol. The DNA fragment was eluted from the polyacrylamide in 
diffusion buffer (0.5 mM ammonium acetate, 10 mM MgSO4, 1 mM EDTA, 0.1% SDS  
[pH 8]) at 55°C for 30 min. After removing excess polyacrylamide by filtration on 
BioRad Poly-Prep chromatography column, the DNA was further purified using a 
Qiaquick Spin column. The DNA concentration was determined using by 
spectrophotometry at 260 nm. Ten picomoles of the gel extracted DNA was 5'-labeled 
using 50 pmol of [γ-32P] ATP and T4 polynucleotide kinase. Gel shift assays were 
performed in buffer C consisting of 50 mM sodium phosphate buffer (pH 7.5) containing 
50 mM NaCl and 10% glycerol. Each 10 µl reaction contained buffer C, 32P-bioO at a 
final concentration of approximately 40 nM, 1 mM ATP, 1 mM MgCl2, 1 µM biotin, and 
various dilutions of BirA.  After incubation for 30 min at room temperature the samples 
were loaded onto a pre-run 5% polyacrylamide gel. The gels were visualized using a 
phosphorimager as described above.  
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In vitro biotinylation assays. Isolation and purification of the apo truncated biotin 
carboxyl carrier protein (apo AccB-87) was carried out using expression from pVC19 in 
strain BL21 (λDE3) as described above. The biotin ligase activity was measured using 
the assay previously described (29, 30). Briefly, the reaction mixture contained 50 mM 
Tris-HCl (pH 8.0), 3 mM ATP, 5.5 mM MgCl2, 5 µM biotin, 25 pmol of [3H] biotin 
(specific activity 32.6 Ci mmol-1), 0.1 mM dithiothreitol, 0.1 mg/mL bovine serum 
albumin and various concentrations of apo protein in a final volume of 100 µL.  The 
reaction was initiated by the addition of purified BirA to a final concentration of 16 nM, 
except for mutant G154D where 100 nM was needed to observe detectable biotinylation 
activity. In order to obtain high levels of radioactive label for accurate readings I 
increased the specific activity 5-fold over that used previously (29, 30) and each vial was 
counted to obtain <5% error. The kinetic constants KM and kcat were determined using 
double reciprocal plots and those for the wild-type enzyme were very similar to those 
previously reported (29, 88). 
Purification and crystallization. BirA mutant K265M was expressed and purified as 
described above. The purified protein solution was exchanged in buffer containing 50 
mM Tris HCl pH 8.0, 150 mM KCl and 10% glycerol. The protein was incubated with 
100 mM ATP and 1 mM Biotin for 1 hour on ice. The final concentration of BirA and 
dsDNA in the mix was 0.15 mM.  
 Crystals were obtained with precipitant containing 10 mM Magnesium acetate, 50 
mM sodium cacodylate pH 6.5, 1.5 M lithium sulfate. This condition gave the crystals 
with the following DNA: 
BioA GC/CG Top. 
CGGACTTGTAAACCAAATTGAAAAGATTTAGATTTAGGTTTACAAGTCGC 
(and the corresponding reverse complement).  
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 Crystals were also grown in 80 mM Magnesium acetate, 50 mM sodium 
cacodylate pH 6.5, 15-20% PEG400 with the following DNA: 
Bio Oper +5 Top. 
TAATCGACTTGTAAACCAAATTGAAAAGATTTAGGTTTAGGTTTACAAGTCTA
CAC (and the reverse complement).  
 Attempts to obtain crystals with the nicked DNA using primers: BioO G Top I, 
BioO Top II and BioO C Bottom, with and without 50 mM spermidine were also tested, 
but the crystals were very small and therefore were not shot. 
2.3 RESULTS 
Isolation of BirA superrepressor mutant strains. The current model of BirA regulation 
(Figure 2.1) argues that several classes of BirA superrepressor mutants are possible, some 
of which would lack enzymatic activity and thus be lethal mutations (7). This is because 
the sole E. coli biotinylated protein AccB, is a subunit of acetyl-CoA carboxylase that 
catalyzes the first step of the fatty acid synthetic pathway. Early blocks in the fatty acid 
synthetic pathway cannot be bypassed by fatty acid supplementation; acetyl-CoA 
carboxylase is essential (7). I therefore isolated birA superrepressor mutants in E. coli 
cells that carried a plasmid (pCY255) encoding Bpl1, the Saccharomyces cerevisiae 
biotin protein ligase. Previous work showed that expression of Bpl1 complemented a 
conditional birA mutation (38). To avoid possible complications of having two BirA 
species present in a cell I deleted the chromosomal birA gene. To avoid lethality I 
constructed the deletion in the presence of a plasmid-borne wild-type copy of birA and 
transduced the mutation into a strain carrying the yeast Bpl1 plasmid (pCY255). The 
successful transduction indicated that Bpll provided full biotin ligase function. The ∆birA 
construct was confirmed to have the expected genomic arrangement by Southern blot 
hybridization (data not shown). To provide an assay for bio operon transcription a 
chromosomal bioF::lacZY promoter fusion was introduced into the ∆birA strain (12). 
Expression of Bpl1 in the ∆birA strain had no effect on bio operon regulation over a wide 
range of biotin concentrations (see below). Homologous recombination catalyzed by the 
phage λred system was then used to replace the coding sequence of the chromosomal 
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bioA gene of the bioF::lacZY strain with a chloramphenicol acetyltransferase (cat) coding 
sequence. This gave VC235, the bioA::cat bioF::lacZY∆birA/pCY255 strain used in the 
mutant selection (Figure 2.2A). The cat gene was used because chloramphenicol is 
bacteriostatic to E. coli at low concentrations and short incubation times (6). This 
property allowed a positive selection for birA superrepressor mutants (Figure 2.2).   
 The hypothesis was that at low concentrations of biotin strain VC235 expressing 
wild-type BirA would be resistant to chloramphenicol due to derepression of the bioA 
promoter and therefore would continue to grow in the presence of the antibiotic (Figure 
2.2B).  In contrast, cells expressing BirA superrepressor proteins would be sensitive to 
chloramphenicol and growth inhibited (Figure 2.2B). Upon addition of antibiotics that 
kill only growing cells (cell lytic ß-lactams) those cells expressing wild-type BirA would 
be killed whereas cells expressing BirA superrepressors would fail to grow due to 
chloramphenicol action and thereby survive. The selection protocol was tested using a 
culture that contained a mixture of two differentially marked strains, one of which carried 
a chromosomal cat cassette insertion. Chloramphenicol was added to the growing culture 
and after two cell doublings ß-lactams (a mixture of ticarcillin and ampicillin) was added 
together with the ß-lactamase inhibitor, clavulanate (Materials and Methods). Following 
lysis of the culture the survivors were plated and scored. The selection resulted in a 
~2x105-fold enrichment of the chloramphenicol-sensitive strain (data not shown). 
 To isolate strains encoding BirA superrepressors the birA gene was subjected to 
PCR mutagenesis (Materials and Methods). The PCR products were ligated to the pVC7 
backbone and the plasmids were transformed into the ∆birA strain VC235 which carried 
the Bpl1 plasmid plus the bioA::cat bioF::lacZY construct. The resulting transformants 
were pooled and grown in defined medium containing 1.6 nM biotin and 3 µg/mL 
chloramphenicol followed by treatment with the ß-lactam plus ß-lactamase inhibitor 
cocktail to enrich for chloramphenicol-sensitive cells. The survivors were plated on 
defined medium plates supplemented with X-gal and 1.6 nM biotin to assay repression of 
bioBFCD transcription. Cells that expressed BirA superrepressors gave white colonies 
due to repression whereas cells expressing wild-type BirA gave blue colonies due to 
derepression at the low biotin concentration. It should be noted that overexpression of 
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wild-type BirA by medium copy number plasmids such as pVC7 results in a degree of 
super-repression due to greater bioO occupancy (10, 36). I found this effect was about 
10-fold which agrees well with the prior estimate of 12-fold using the same vector 
plasmid (10). However, the dynamic range of BirA regulation is sufficiently large 
(several 100-fold) that medium copy number plasmids could be used to facilitate the 
genetic manipulations.  
 The plasmids recovered from white colonies were transformed into strains VC218 
and VC233. Transformants of the ΔbirA ΔlacZY bioF::lacZY/pCY255 strain, VC218, 
were used to assay  β-galactosidase levels in cultures grown with 1.6 nM biotin (Figure 
2.3).  I sequenced the birA genes of candidate strains that showed 5 to 10-fold reductions 
in β-galactosidase activity relative to the strain carrying the BirA wild-type plasmid 
pVC7. Five of the eight mutant genes sequenced had multiple base substitutions that 
resulted in several amino acid substitutions whereas the remaining three mutants (5A, 8A 
and 13B) each contained a single amino acid substitution (Figure 2.3A). The multiple 
mutant genes (1A, 6A, 12A, 16B and 3C) were deconvoluted by site-directed 
mutagenesis into single and double mutants (Figure 2.3B and 2.3C) in order to identify 
the amino acid residue substitution(s) responsible for superrepressor phenotype (Figure 
2.3D). In most cases only a single mutation was required for the superrepressor 
phenotype (an exception is shown in Figure 2.3C) and thus I limited our analyses to those 
proteins (Figure 2.3D). 
In vivo characterization of the birA mutants. Although a majority of the superrepressor 
BirA mutants were expected to be defective in carrying out the essential ligation of biotin 
to AccB, this was not the case. Only one such mutant, G154D BirA, was isolated. To test 
the in vivo ligation abilities of the mutant BirA proteins, strain VC618 (∆birA::kan 
bioF::lacZY/pVC18) was transformed with each of the mutant BirA plasmids at 30°C. 
These strains were then cured of the temperature-sensitive yeast Bpl1 plasmid, pVC18, 
by growth at 42°C. Each of the mutant proteins with the exception of mutant G154D 
BirA, allowed robust growth of the ∆birA strain comparable to that given by the plasmid 
encoding wild-type BirA even at the minimal biotin concentration (1.6 nM) (data not 
shown). The G154D BirA strain also grew, but more slowly; an additional day was 
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required for visible colonies to appear. To quantify these observations growth curve 
analyses of the strains were done in medium supplemented with biotin at different 
concentrations. Only the strain expressing G154D BirA showed a growth defect at low 
biotin concentrations (1.6 and 4 nM) (Figure 2.4A and B). Superrepressor mutant alleles 
generally show genetic dominance over the wild-type allele and thus I tested the plasmid-
borne mutant alleles for this property. All of the mutant alleles were dominant over the 
chromosomal wild-type allele in that they gave levels of bio operon expression of 
approximately 40 to 200–fold lower than that of the plasmid borne wild-type allele when 
grown with 1.6 nM or 4 nM biotin (data not shown).  
 The rate of bio operon transcription responds to the concentrations of both biotin 
and the unmodified forms of biotin accepting proteins and thus is derepressed upon high-
level expression of a biotin accepting protein even at high biotin concentrations (36). The 
biotin accepting protein can be AccB, heterologous proteins from other organisms or 
even a small peptide (37, 101). I therefore asked if the super-repression phenotypes of the 
mutant proteins could be relieved by increased biotin acceptor protein concentrations. 
The most physiologically relevant biotin acceptor protein is AccB. However, 
overexpression of AccB is toxic to E. coli unless AccC, the biotin carboxylase subunit of 
acetyl CoA carboxylase encoded by the downstream gene is simultaneously 
overexpressed (1, 59) probably because AccB and AccC form a stoichiometric protein 
complex (31). The effects of AccB-AccC overexpression from plasmid pCY705 were 
quantitated by  β-galactosidase assays of cultures grown with different biotin 
concentrations. As a negative control pCY705 was replaced with pCY730, which 
encodes a K122R AccB that can neither be biotinylated nor act as a regulatory ligand (1).  
 Biotin operon regulation shows the greatest response over biotin concentrations 
from 4 to 40 nM (1, 11, 36, 101). The strains expressing the I187T, K267M, Y178C, 
P143T and M310L BirA proteins all responded to over-expression of AccB (plus AccC) 
in a manner similar to that of the strain expressing wild-type BirA (Figure 2.5A-F) except 
that the derepression levels of the mutant BirA strains were 2 to 3-fold lower than the 
wild-type levels (Figure 2.5J-K). In contrast the strain expressing the G154D mutant 
BirA showed no derepression of bio operon transcription upon AccB-AccC 
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overexpression (Figure 2.5G). I hypothesized that if the observed lack of derepression 
was due to the inability of the G154D BirA to interact with AccB, then the mutant protein 
might remain able to biotinylate the peptide-85 sequence, a 15-residue biotin accepting 
peptide isolated by Schatz (97). The peptide-85 sequence is as effective a biotin acceptor 
as AccB (16), despite sharing very little sequence similarity with the AccB biotinylation 
site (101). Expression of the peptide-85 sequence as a fusion to maltose binding protein 
(101) failed to relieve BirA G154D repression of bio operon transcription (Figure 2.5H), 
although it relieved repression by wild-type BirA (Figure 2.5I).  These observations 
strongly suggest that BirA G154D is defective in the transfer of the biotin moiety from 
biotinoyl-adenylate to the acceptor. 
 Strains that expressed G154D BirA from a plasmid showed a superrepressor 
phenotype and grew slowly at low biotin concentrations. Since these attributes could 
depend to some degree on plasmid copy number and the use of a foreign promoter, I 
replaced the wild-type chromosomal birA with the mutant allele encoding BirA G154D 
by use of a counter-selection strategy (108). Given the lower chromosomal expression 
level it seemed likely that introduction of the mutant allele into the chromosome would 
be lethal and thus the recipient strain carried the yeast Bpl1 plasmid to provide ligase 
activity. Following construction and validation of the allele replacement I attempted to 
transduce the G154D mutation into a wild-type strain. Transduction proceeded readily 
when the recipient strain contained a plasmid that encoded ligase activity whereas 
transductions into a strain that carried an empty vector repeatedly failed, indicating that 
the G154D birA allele was a lethal mutation.   
 To provide more direct evidence of lethality I introduced a temperature-sensitive 
mutation in DNA polymerase I into strains carrying the Bpl1 plasmid and chromosomal 
copies of genes encoding either the wild-type or G154D mutant BirAs (strains VC779 
and VC780). In the absence of DNA polymerase I activity the replication origin of the 
Bpl1 plasmid is inactive (63, 73). At the permissive temperature of 30ºC, the polA(Ts) 
mutation was readily transduced into both the G154D birA strain VC779 and the wild-
type birA strain VC780. When shifted to the non-permissive temperature of 42°C to drive  
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out the Bpl1 plasmid strain VC801 (birAWT) grew well whereas strain VC802 (birAG154D) 
failed to grow, thereby demonstrating the lethality of the G154D birA allele in its native 
chromosomal location (Figure 2.6B).  
 The effect of chromosomal expression of the G154D protein on the bio operon 
regulation was determined by β-galactosidase assays of cultures grown with a range of 
biotin concentrations (the strain carried the Bpl1-encoding plasmid for viability). No 
detectable derepression of the bio operon was seen at 1.6 nM biotin, indicating that the 
presence of the Bpl1-encoding plasmid did not effect BirA regulation (Figure 2.6A). A 
similar absence of regulation by Bpl1 resulted when the chromosomal mutation was the 
birA1 allele (12) (data not shown). 
Binding affinities of the BirA mutant proteins for bioO. To further characterize the 
mutant BirA proteins I purified C-terminal hexahistidine-tagged derivatives of six mutant 
proteins together with wild-type BirA and the AccB-87, the biotin domain of AccB 
(Figure 2.7). The most straightforward explanation for the superrepressor phenotypes of 
the mutant BirA proteins is that, they would bind the bio operator more tightly than the 
wild-type protein. To test if this was the case I carried out electromobility shift assays 
(EMSAs) using a 112-bp biotin operator duplex DNA and the purified BirAs. EMSA 
analyses were performed on wild-type BirA and four mutant proteins, G154D, I187T, 
M310L and K267M, which covered the range of in vivo phenotypes observed. 
Unliganded BirA preparations of each of the proteins (with the exception of mutants 
G154D and K267M proteins) were obtained as described in “Materials and Methods”. 
Since in vivo and in vitro experiments indicated that mutant G154D was defective in 
transfer of the biotin moiety to AccB-87, no attempts to purify the unliganded form of 
this protein were made. Unliganded BirA proteins were obtained by expression of the 
BirA proteins in a ∆bio strain carrying a plasmid that expressed AccB-87 from an 
araBAD promoter in medium containing a minimal (1.6 nM) concentration of biotin.  
The rationale was that biotin starvation plus the coupled over-expression of BirA and 
AccB-87 would result in transfer of any biotin bound to BirA (either as the free acid or as 
biotinoyl-adenylate) to AccB-87 to give unliganded BirA preparations. This approach 
allowed purification of apo-BirA derivatives that gave no observable mobility shifts 
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unless both biotin and ATP were present (Figure 2.8A). For comparison the K267M BirA 
protein showed operator binding in the absence of added biotin when ATP was present 
suggesting that the active site contained biotin derived either from intracellular biotin or 
biotin formed by hydrolysis of the adenylate during protein purification.  
 The mobility shift experiments were done over a range of BirA concentrations 
(500 nM-31.25 nM). All of the mutant proteins showed increased ability to bind the bio 
operator in that; significant operator binding was seen at concentrations, (31.25 nM and 
61.5 nM) at which wild-type BirA showed barely detectable binding. Moreover, at 250 
nM BirA the mutant proteins bound the probe almost quantitatively whereas, a significant 
fraction of the probe incubated with wild-type BirA remained unbound. Three of the 
mutant BirAs, M310L, K267M and G154D, showed increased operator binding across 
the BirA concentration gradient whereas, BirA I187T had only slightly enhanced binding 
(Figure 2.8 B-E). Due to the variation seen in binding by the wild-type BirA, the wild-
type protein was assayed in parallel with each of the mutant proteins. The observed 
variable operator binding of wild-type BirA precluded quantitative analysis of these data. 
Ligation abilities of the mutant BirA proteins. The purified BirAs were first 
qualitatively tested for the ability to synthesize the BirA reaction intermediate, biotinoyl-
adenylate, in the presence of biotin and [α-32P]-labeled ATP. Since all of the mutant 
proteins allowed growth of the ∆birA strain, they were expected to synthesize the 
biotinoyl-adenylate intermediate in vitro. Indeed, each of the mutant proteins synthesized 
biotinoyl-adenylate when [α32P]-ATP and biotin were added as substrates (Figure 2.9). 
We also tested transfer of the biotinoyl-adenylate biotin moiety to AccB-87, the carboxyl 
terminal half of AccB, which accepts biotin as well as the full-length protein (78). In this 
assay addition of AccB-87 to the completed biotinoyl-adenylate synthesis reaction should 
result in disappearance of biotinoyl-adenylate and the appearance of AMP. Each of the 
mutant proteins except BirA G154D gave this result (Figure 2.9A and B). G154D BirA 
was almost completely defective in biotin transfer in vitro (Figure 2.9A). With the 
exception of BirA mutant G154D, no detectable differences were observed between the 
mutant and wild-type BirAs in time course assays (data not shown).  
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Kinetics of AccB-87 biotinylation. To evaluate the abilities of the mutant BirA proteins 
to ligate biotin to AccB in vitro, the kinetic constants for AccB-87 were determined using 
steady state kinetics. The in vitro biotinylation activities of the three purified mutant 
BirAs I187T, M310L and G154D and of the wild-type BirA were determined in assays 
performed at saturating levels of biotin and Mg-ATP (Materials and Methods). As shown 
by the kinetic constants, (Table 2.3) BirA proteins I187T and M310L proteins did not 
differ significantly from those of wild-type BirA in their Michaelis–Menten constants for 
the biotin acceptor substrate. However, as expected from the indirect experiments of 
Figure 2.9A, BirA G154D was extremely defective in biotinylation of AccB-87. 
Biotinylation catalyzed by G154D BirA could be detected only when the enzyme and 
substrate concentrations of the assay were increased to 100 nM and 75 µM, respectively. 
Reliable kinetic constants for BirA G154D could not be calculated because saturating 
AccB-87 concentrations could not be attained. However, it is clear that the substitution of 
aspartate for G154 results in a ligase that has at least a 200- to 300-fold decrease in the 
ability of the protein to productively interact with AccB-87. 
Crystallization studies. To obtain co-crystal structure of BirA-Bio-5ʹ′-AMP bound to 
DNA I carried out several crystallization studies in collaboration with Dr. Satish Nair and 
his graduate student Dr. Vinayak Agarwal. I expressed and purified two superrepressor 
mutants K267M and G154D and also the double mutant BirA K267M G154D. The single 
mutant BirA G154D and the double mutant BirAK267M G154D did not express well and 
the double mutant precipitated during purification steps. Unlike the in vitro experiments 
mentioned above, large quantities (5-10 mg/mL) of purified proteins are required to set 
up crystallization studies, therefore it was not possible to set up crystallization screens 
with these two BirA mutants. Mutant K267M gave crystals under the two conditions 
mentioned above in the Materials and Methods, however none of the crystals diffracted 
X-rays. I also tried the nicked DNA (Table 2.4) with mutant K267M with and without 50 
mM spermidine but the crystals were very small crystals and therefore the crystals were 
not shot. Vinayak also set up screens with 50 mM spermine and 50 mM spermidine using 
the crystallization screens-Hampton Natrix and Hamptom MembFac but no hits were 
obtained. Different DNA constructs mentioned in Table 2.4 were also tested but no 
positive hits were obtained. For the two conditions mentioned in the Materials and 
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Methods, Vinayak extensively washed ~15 crystals each in the mother liquor, dissolved 
the crystals by heating ~50°C in TAE buffer and ran them on 3% agarose gel. Both 
conditions had DNA bound to BirA in the crystals (V. Agarwal, personal communication 
with V. Chakravartty). 
2.4 DISCUSSION 
 Prior genetic selections for birA mutants resulted in isolation of strains having 
decreased abilities to repress bio operon expression, many of which were also defective 
in biotin utilization (12). All of the mutant alleles tested were recessive to the wild-type 
allele indicating that they were loss of function mutations (12). Subsequent work on 
several of these mutant strains showed that the defects in biotin utilization reflected 
compromised ligase activity due to decreased affinities for biotin and/or biotinoyl-
adenylate (32, 64). I report isolation of the first gain of function (genetically dominant) 
birA superrepressor alleles. BirA superrepressor strains were isolated by use of a 
chloramphenicol resistance cassette as a negative selection, a manipulation that may be 
generally applicable. The selection method was surprisingly efficient such that BirA 
superrepressor strains were readily isolated and showed the expected in vivo phenotype. 
The current model of BirA function implies that an appreciable fraction of superrepressor 
mutations should be lethal. For example BirA proteins that bind bioO in the absence of 
biotinoyl-adenylate, would not respond to biotin limitation or the need for protein 
biotinylation. Although the selection method ensured survival of strains carrying lethal 
mutations, I isolated only one lethal mutation (BirA G154D). The finding that 
superrepressor strains having mutations in the catalytic domain retained ligase activity 
indicates that communication of the catalytic domain with the DNA binding domain is 
more complex than previously appreciated: normal ligase activity does not necessarily 
result in normal repression.  
 There is good evidence that BirA undergoes diverse interactions among the three 
domains during its physiological roles, and our data provide further proof of this. A prime 
example in the prior literature concerns the N-terminal DNA binding domain. In all 
currently available crystal structures (e.g., Figure 2.10A) the domain appears well 
removed from the catalytic and C-terminal domains and thus it would seem that, deletion 
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of this domain would leave the ligase activity intact. However, deletion of the DNA 
binding domain results in greatly weakened binding of biotin which compromises 
biotinoyl-adenylate synthesis (120). The ability to retain biotinoyl-adenylate in the active 
site is also impaired (120) and the N-terminal deletion mutant is unable to grow at 
physiological biotin concentrations (Chapter 3). Another example of inter-domain 
communication is the restructuring of loops in the C-terminal domain observed upon 
binding of a biotinoyl-adenylate analogue to the catalytic domain (65, 119). Among our 
mutants the phenotypes of the I187T and K267M superrepressor BirAs probably reflect 
disturbances in inter-domain communications. The I187 substitution (I187T) involves a 
residue implicated in packing interactions between the adenylate binding loop and an 
interfacial loop (119) whereas the K267M substitution is located within the sequence that 
connects the catalytic and C-terminal domains (Figure 2.10A). Thus residue K267, 
although exposed to solvent and removed from both the dimer interface and the DNA 
binding domain, somehow modulates operator binding, the property of a domain that is 
far distant in the extant crystal structures. The most profound mutation I isolated was the 
G154D BirA, a lethal mutation in its native chromosomal context that had the strongest 
superrepressor phenotype. This protein was severely deficient in binding the AccB biotin 
acceptor protein and unable to transfer biotin from biotinoyl-AMP to the acceptor.  
Although the biotin transfer defect alone could explain its superrepressor phenotype, the 
G154D BirA also showed increased affinity for the operator DNA. The finding that a 
single point mutation affects both biotin transfer and DNA binding further illustrates 
interactions among the domains of BirA. 
Since BirA dimerization is required for bioO binding, superrepressor mutations 
that facilitate or stabilize dimerization were expected. The BirA-biotinoyl-adenylate 
complex forms dimers at protein concentrations of 5-10 µM whereas operator binding 
occurs in the range of 30 nM (15, 77, 105, 121). Therefore a large window exists within 
which increased operator binding by improvement of the dimerization properties of BirA 
could be obtained. Indeed, the amino acid substitutions of several of the BirA 
superrepressors isolated, P143T, Y178C and M310L are located at or adjacent to the 
dimerization interface (Figure 2.10B) and thus may directly affect dimerization.  
Unfortunately, it is not straightforward to measure BirA dimerization because the 
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monomer and dimer forms are in rapid equilibrium. The wild-type BirA dimer has a half-
life of minutes (102), a time scale incompatible with size exclusion chromatography.  
Moreover, size exclusion chromatography would dilute and separate the two forms and 
thereby skew the equilibrium. Hence, although superrepressor BirA dimers may be more 
stable than the wild-type protein, no valid comparison with the wild-type protein could be 
made. Such measurements must be made in free solution, a technically demanding task 
that we have chosen to defer pending crystallization trials of the mutant proteins.  
 The present crystal structures give no clues to the modes of interaction of the 
DNA binding domain with the catalytic and C-terminal domains although data in this 
study and elsewhere indicate that these interactions are key to both functions of BirA. 
This situation remains despite many attempts with the wild-type protein (B. W. 
Matthews, personal communication with Dr. Cronan). Our hypothesis is that the 
increased binding affinities of superrepressor BirA proteins for bioO should increase the 
probabilities of obtaining co-crystal structures. However, it is unclear which (if any) of 
the mutant proteins will provide a high quality structure. Therefore, we have adopted a 
“bottom line” strategy in which several superrepressor mutant proteins have been 
subjected to crystallization trials with operator DNA and small molecule ligands.  If 
successful, the BirA proteins that give high quality BirA-bioO co-crystal structures will 
be the prime candidates for further study. I have carried out preliminary crystallization 
studies in collaboration with Dr. Satish Nair and his graduate student Dr. Vinayak 
Agarwal. We tested three different BirA mutants namely K267M, G154D and the double 
mutant BirA K267M G154D. We were successful in getting crystals with mutant K267M 
bound to DNA. However, none of the crystals diffracted and we were unable to obtain 
usable data. These results are promising because all the crystals had DNA bound to BirA. 
Moreover, the low resolution is typical of such complexes and the way to improve the 
data is to try co-crystallization with oligonucleotides of different length, with different 
overhangs and there are other superrepressor mutants that can be used to set up the 
screen. If successful, the BirA proteins that give high-quality BirA-bioO co-crystal 
structures will help bridge the gap in our understanding of the bio operon regulation. 
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2.5 TABLES AND FIGURES 
Table 2.1.  Bacterial strains used in this chapter. 
Strain  Relevant Genotype or Description 
Reference or 
Derivation 
MG1655 E. coli K-12 wild-type Lab collection 
MC1061 
araD139 Δ(ara–leu)7696 Δ(lac)X74 rpsL 
hsdR2 (114) 
JT33 MG1655 lacZY::cmlR (41) 
JT34 MG1655 ΔlacZY (41) 
BL21 (λDE3) ompT, hsdSB (rB–, mB–), dcm, gal, (λDE3) Novagen 
DH5α Δ(argF-lacZ)U169 glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 
thi-1 hsdR17 Laboratory collection 
CY481 Derived from strain BM4092 by 
transduction to birA+ (36) 
EL117 ALS225 ΔrecA::tetR A. Kuzminov lab 
collection 
AK25 polA12 plus closely linked Tn10 A. Kuzminov lab 
collection 
CS100 ΔlacX74, sgrS::cat-sacB, mini λTet (112) 
VC146 EL117/pYFJ32, pSRK46 This study 
VC150 VC146 ΔbirA::kmR KmR-insertion 
VC125 MG1655/pCY255 This study 
VC156 ΔbirA::kmR VC125 X P1(VC150) 
VC203 bioF::lacZY-kmR CY481 
VC209 ΔbirA::FRT 
VC156, KmR removed 
by pSRK20 
VC205 ΔbirA lacZY::cmlR VC209 x P1(JT33) 
VC212 ΔbirA ΔlacZY::cmlR bioF::lacZY-kmR VC205 X P1(VC203) 
VC218 ΔbirA ΔlacZY bioF::lacZY 
VC212 CmlR and KmR- 
cassettes removed by 
flp recombinase 
expression 
VC228 JT34 bioF::lacZY-kmR This study 
VC230 VC218/pSRK46 This study 
VC233 JT34 bioF::lacZY 
Insertion removed by 
pCP20 	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Table 2.1. (cont.) 
VC235 VC218 ΔbioA::cat 
Replacement of bioA 
with cat gene by 
homologous 
recombination 
VC537 VC233/pVC18 This study 
VC618 VC537 birA::kmR VC537 x P1(VC156)  
VC730 JT34 bioF::lacZY/pCY255 pSRK46 This study 
VC772 VC730 birA::cat-sacB 
Replacement of birA 
with a cat-sacB gene 
cassette by homologous 
recombination 
VC776 VC730 birA::cat-sacB VC730 x P1(VC772) 
VC778 birAWT bioF::lacZY 
Replacement of 
birA::cat-sacB with 
birAWT using 
homologous 
recombination 
VC779 birAG154D bioF::lacZY/pCY255 
Replacement of 
birA::cat-sacB with 
birAG154D using 
homologous 
recombination 
VC780 VC778/pCY255 This study 
VC801 VC780 polA12::Tn10 VC780 x P1(AK125) 
VC802 VC779 polA12::Tn10 VC779 x P1(AK125) 
Plasmids   
pEAK-1 pSC101(Ts), AmpR (27) 
pCY255 plasmid encoding Bpl1 of S. cerevisiae  
pCP20 Flp expression plasmid, AmpR, CmlR (40) 
pKD46 
oriR101, red recombinase expression 
plasmid (40) 
pKD3 oriRγ template plasmid, CmlR (40) 
pKD4 oriRγ template plasmid, KmR (40) 
pBAD33 
p15A ori, arabinose inducible expression 
vector, CmlR (51) 
pET19b T7 promoter expression vector, AmpR Novagen 
pET16b T7 promoter expression vector, AmpR Novagen 
pACYC184 
p15A ori, low copy number, CmlR and 
TetR (93) 	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Table 2.1. (cont.) 
pCY730 
pKK223-3 containing accBK122R and 
accC under Ptac control (1) 
pCY705 
pKK223-3 containing accB and accC 
under Ptac control (1) 
pMS421 plasmid encoding lacIQ, SpecR (49) 
pYFJ32 
pQE2- encoding N-terminal Hexahistidine 
tagged BirA Y. Jiang unpublished 
pSRK46 pKD46, SpecR S. R. Khan unpublished  
pSRK20 pCP20, CmlR and SpecR S. R. Khan unpublished  
pCY759 
plasmid encoding Maltose binding protein 
fusion to biotin accepting peptides 85 (101) 
pVC7 pACYC184 encoding BirA, TetR This study 
pVC18 pEAK-1 encoding BPLI, AmpR This study 
pVC10 pET19b encoding C-terminal 
hexahistidine tagged BirA, AmpR This study 
pVC19 
pET16b encoding C-terminal BCCP, 
AmpR This study 
pVC17 
pBAD33 encoding C-terminal BCCP, 
CmlR This study 
pVC11 pET19b encoding C-terminal 
hexahistidine tagged BirA I187T This study 
pVC12 pET19b encoding C-terminal 
hexahistidine tagged BirA K267M This study 
pVC13 pET19b encoding C-terminal 
hexahistidine tagged BirA Y178C This study 
pVC14 pET19b encoding C-terminal 
hexahistidine tagged BirA P143T This study 
pVC15 pET19b encoding C-terminal 
hexahistidine tagged BirA M310L This study 
pVC16 pET19b encoding C-terminal 
hexahistidine tagged BirA G154D This study 
pVC20 pACYC184 encoding BirA I187T This study 
pVC21 pACYC184 encoding BirA K267M This study 
pVC22 pACYC184 encoding BirA Y178C This study 
pVC23 pACYC184 encoding BirA P143T This study 
pVC24 pACYC184 encoding BirA M310L This study 
pVC25 pACYC184 encoding BirA G154D This study 
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Table 2.2. Oligonucleotide primers used in this chapter. 
Oligonucleotide Sequence 
VCA5 GCCTGGCAGTGCAACCGC 
VCA6 CCCCACCTATTTGCATCCCTTTTAGCT GG 
VCA10 
TTTATTGGTGCATCAGGTGAAGTGAGCGCAGTGGAGACA
ATTTCATGA AGTAATGTGTAGGCTGGAGCTGCTTCGA 
VCA11 
TAATTTGCAGGGGAGCGAATACTCCCCTTTCTTATTTTCT
GCACTAC GCAGCATATGAATATCCTCCTTAG 
VCA12 GTCTGGCTTGAGCCTGAAGTCCGC 
VCA13 GCGGTAGAAGAGGTCAGACTACGC 
VCA20 
GTTGTTAATTCGGTGTAGACTTGTAAACCTAAATCTTTTC
AATTTGGTTTA 
CAAGTCGATTATGGAGAAAAAAATCACTGG 
VCA21 
CTTGTTTGCAGAAAGTGTAGCCAGAAACCCTCACGCGGA
CTTCTCGTTACG CCCCGCCCTGCC 
VCA57 
GGCGCGAGCGCCTTATCCGACCAACATATCATAACGGAG
TGATCGCATTGT GTGTAGGCTGGAGCTGCTTCGA 
VCA58 
CGGTATCCGTTCCGGTGACAAAATAACGTTTACTCACGAG
CAATCACTCCC ATATGAATATCCTCCTTAG 
VCA59 GTCGCTTAAGCAATCAATGTCGG 
VCA60 GCACAACTGGCGACAGTTTTCC 
VCA69 CCGAATTCAGTGGAGACAATTTCATGAAG 
VCA70 GCGCCATGGTTATTTTTCTGCACTACGCAGG 
VCA71 GCGGCAATTTATCGCCATCGCGC 
VCA72 GCGGTGAGCCATGGGGCTTCTCC 
VCA84 CCGCCTCTAGATTTCAATTGTAAATATTGTATACTCCCG 
VCA85 GGATCCCCGGGTAGTCCTACATCGCCTTC 
VCB8 TCACTCTGGCGAGCAGTTGGGTGAAACGC  
VCB9 GCGTTTCACCCAACTGCTCGCCAGAGTGA 
VCB10 CCACTGAAATTGATTGCCATGTTAGCGAACGGTGAAT 
VCB11 ATTCACCGTTCGCTAACATGGCAATCAATTTCAGTGG 
VCB12 GCAAGCTGGCAGGCATTCTGGTGGAGC 
VCB13 GCTCCACCAGAATGCCTGCCAGCTTGC 
VCB14 GCCACTTAAATTGATTGCCCTGTTAGCGAACGGTGAATT 
VCB15 AATTCACCGTTCGCTAACAGGGCAATCAATTTAAGTGGC 
VCB16 GCGCCATGGATGAAGGATAACACCGTGCC 
VCB17 CGCGGATCCTTAATGATGATGATGATGATGTTTTTCTGC 
VCB44 CGAATTCGAGCTCTAAGGAGGAGACCAATGGAAGCGC 
VCB45 CAGCCAAGCTTTTACTCGATGACGACCAG 	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Table 2.2. (cont.) 
VCB36 GGCAAGATCGTCCGTTGTCATAATCGAC 
VCB37 GCCATGGGGCTTCTCCAAAACGTG 
VCB57 GATATACCATGGAAGCGCCAGCAGC 
VCB58 GCCGGATCCTTACTCGATGACGACCAGCG 
VCC44  
GCAAATAATTTGCAGGGGAGCGAATACTCCCCTTTCTTAT
TTTTCTGCACT ACGCATCAAAGGGAAAACTGTCCATAT 
VCC5 GGAATAATAAAACCCTGGTTGGGCGGTGAAATATCCC 
VCC6 GGGATATTTCACCGCCCAACCAGGGTTTTATTATTCC 
VCC49 
ATTGGTGCATCAGGTGAAGTGAGCGCAGTGGAGACAATT
TCATGAAGG ATAACAAATGAGACGTTGATCGGCACG 
VCC50 
GCCTGAAGTCCGCTTTATTGGTGCATCAGGTGAAGTGAGC
GCAGTGGAGAC AATTTCATGAAGGATAACACCGTGC 
VCC51 
GCGGTAGAAGAGGTCAGACTACGCAAATAATTTGCAGGG
GAGCGAATACTC CCCTTTCTTATTTTTCTGCACTACGCAG 
VCC52 GGTGAAAAATTTAATGTCTGGCTTG 
VCC53 CCAGTTTAATCCTGACGAAAAGTGCTAATC 
VCB73 GGTTTAAGTCTGGTTATCGATATCGTGATGGCGGAAG 
VCB74 CTTCCGCCATCACGATATCGATAACCAGACTTAAACC 
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Table 2.3. Kinetic constants for biotinylation of AccB-87 by wild-type BirA and three 
mutant BirA proteinsa 
 
 Wild-Type I187T 
Mutant 
M310L 
Mutant 
G154D 
Mutant 
KM (µM) for AccB-87 5.4  ± 0.76 12.8 ± 2.35 8.6 ± 1.5 170 
kcat (sec-1) 0.86 ± 0.7 1.37  ± 0.04 1.22 ± 0.3 ND 
kcat/KM (M-1sec-1) x 103 164.3 ± 28.8 116.1 ± 2.4 140 ± 10 ND 
 
aThe wild-type and mutant derivatives of BirA were assayed by in vitro biotinylation 
reactions over a range of AccB-87 protein concentrations as described in Materials and 
Methods. Results are presented as the average and standard error of triplicate 
determinations. ND, not determined.  
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Table 2.4. Oligonucleotide primers used in the crystallization studies. 
Bio Oper A/T Top 
AGACTTGTAAACCAAATTGAAAAGATTTAGGTTTACAA
GTCT 
Bio Oper A/T Bot 
AGACTTGTAAACCTAAATCTTTTCAATTTGGTTTACAAG
TCT 
Bio Oper + 5 Top TAATCGACTTGTAAACCAAATTGAAAAGATTTAGGTTT
ACAAGTCTACAC 
Bio Oper + 5 Bot GTGTAGACTTGTAAACCTAAATCTTTTCAATTTGGTTTA
CAAGTCGATTA 
BioO G Top I GGACTTGTAAACCAAATTGAA 
BioO Top II AAGATTTAGGTTTACAAGTC 
BioO C Bottom 
CGACTTGTAAACCTAAATCTTTTCAATTTGGTTTACAAG
TC 
BioA Oper Lower 
GACTTGTAAACCTAAATCTTTTCAATTTGGTTTACAAGT
C 
BioA Oper Upper 
GACTTGTAAACCAAATTGAAAAGATTTAGGTTTACAAG
TC 
BioA GC/CG Top  CGGACTTGTAAACCAAATTGAAAAGATTTAGATTTAGG
TTTACAAGTCGC 
BioA GC/CG Top  GCGACTTGTAAACCTAAATCTAAATCTTTTCAATTTGGT
TTACAAGTCCG 
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Figure 2.1. The BPL reaction and E. coli biotin operon regulation.  Panel A shows 
the biotin protein ligase (BPL) activity of BirA. Panels B, C and D show the general 
model of bio operon regulation. Green ovals denote BirA, tailed blue ovals are AccB, 
black dots represent biotin and black dots with red pentagons denote biotinoyl-adenylate 
(bio-5'-AMP). Panel B shows the transcriptionally repressed state whereas panels C and 
D, respectively, show derepression of bio operon transcription engendered by either 
excess unbiotinylated AccB acceptor protein or by biotin limitation. Figure modified 
from reference (101). 
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Figure 2.2. Selective enrichment for BirA superrepressor mutant strains. (A) The E. 
coli biotin operon consists of five structural genes that are arranged in a bi-directional 
operon (upper line). BirA represses the transcription of these genes by binding to bioO, a 
40-bp inverted repeat sequence (modified from 12). The native bio operon was modified 
(lower line) by transduction of the bioF::lacZY fusion of strain CY481 into strain VC212.  
The bioA gene of the resulting construct was then replaced with the cat gene (which 
encodes chloramphenicol resistance) using recombination catalyzed by the phage λ red 
system (40) to give strain VC235, the strain used in the selection-enrichment protocol. 
The lacZY genes are fused to the rightward bio promoter resulting in a lactose-positive 
phenotype when the bio operon transcription is derepressed and a lactose-negative 
phenotype when the operon is repressed (12). The strain also carried a deletion of the 
chromosomal lactose operon and was a biotin auxotroph due to insertion of the lac genes 
into bioF. When grown with low biotin concentrations superrepressor mutants would 
have a higher affinity for the biotin operator such that the strains would be 
chloramphenicol sensitive. In contrast the strains encoding wild-type copy of BirA would 
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Figure 2.2. (cont.) 
be resistant to chloramphenicol and continue growth in the presence of the antibiotic. The 
selection results from addition of a mixture of ß-lactams (ticarcillin and ampicillin) plus a 
ß-lactamase inhibitor (clavulanate) which kills only growing (chloramphenicol-resistant) 
cells whereas the chloramphenicol sensitive cells survive. Finally, the surviving cells 
were plated on defined medium plates supplemented with X-gal and 1.6 nM biotin to 
screen for colonies having a superrepressor phenotype (white colonies rather than the 
wild-type blue colonies).  
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Figure 2.3.  
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Figure 2.3. (cont.)  
Isolation and characterization of BirA candidates exhibiting superrepressor 
phenotypes. Single colonies were streaked on defined medium plates supplemented with 
1.6 nM biotin and X-gal for phenotypic confirmation. Liquid cultures grown in the same 
medium were then assayed for bio operon transcription by β-galactosidase activity 
(Materials and Methods). The birA inserts of the plasmids encoding the superrepressor 
BirAs were then sequenced.  Panel A shows the transcriptional activities and mutations of 
the mutants studied whereas panel B illustrates the deconvolution of the double mutants 
1A and 6A (which shared the I187T mutation) to identify the mutations causing the 
superrepressor phenotype.  Panel C shows the deconvolution of the 12A triple mutant. 
The single mutations were generated by site-directed mutagenic repair of each mutant 
allele with the wild-type sequence. Strains carrying the plasmids encoding single mutant 
BirAs were then assayed for  β-galactosidase activity. Finally (panel D) the  β-
galactosidase activities of the plasmid borne single mutant superrepressor strains chosen 
for in vivo and in vitro analysis were compared with the wild-type strain and with each 
other. Error bars denote the standard error. 
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Figure 2.4.  Complementation of the E. coli birA ∆bioABFCD strain by expression of 
either wild-type BirA (panel A) or G154D BirA (panel B) from a medium copy 
number plasmid.  The strains were assayed for growth in defined medium liquid 
cultures supplemented with various concentrations of biotin as described in the Materials 
and Methods section. The differing biotin concentrations are indicated by the colored 
symbols to the right of panel B. Each growth curve assay was carried out in triplicate and 
the average was used in this plot. Growth was measured by optical density at 600 nm. 
Note that the Y-axis is plotted in a log scale. Panels A and B have the same color code. 
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Figure 2.5. Regulation of bio operon expression in BirA mutant strains upon over-
expression of biotin acceptor proteins. Expression of the bio operon in cultures grown 
with various concentrations of biotin assayed by use of  β-galactosidase production from 
the chromosomal bioF::lacZY fusion.  The strains used were derivatives of strain VC618 
cured of plasmid pVC18 that carried the lacIQ plasmid pMS421 plus two compatible 
plasmids, one of which encoded a BirA mutant protein and the other encoded wild-type  
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Figure 2.5. (cont.)  
AccB plus AccC or AccB K122R-AccC or the biotin accepting peptide-85 fusion protein. 
The AccB-AccC and AccB K122R-AccC plasmids were pCY705, and pCY730, 
respectively, whereas the plasmid pCY759 encoded the maltose-binding protein fused to 
biotin accepting peptide-85.  The AccB K122R protein that is unable to accept biotin 
served as control.  The most responsive range of biotin concentrations (X-axis) was 4 to 
40 nM. Derivatives of strain VC618 carrying the wild-type or the mutant BirA plasmids 
plus pCY705 () or pCY730 () were induced with 0.1 mM IPTG. The experiments 
were repeated three times in their entirety and the results were essentially identical to 
those shown. Also included are strain VC618 derivatives that carried the peptide-85 
plasmid pCY759 and plasmids encoding either the BirA mutant G154D (H) or wild-type 
BirA (I). Symbols () represent assays with cultures that were induced with 0.1 mM 
IPTG whereas () represents assays of uninduced cultures. Note that the Y- axis is 
plotted on a log scale. The data of panels J and K are from three independent experiments 
and demonstrate the effects of AccB overexpression on the regulation of the bio operon 
by the wild-type and birA mutant strains.  The wild AccB-AccC expression (J) was 
performed at 40 nM biotin (repression conditions) whereas the AccB K122R-AccC (K) 
expression was assayed at 4 nM (de-repression conditions). Open bars indicate cultures 
induced with 0.1 mM IPTG whereas the solid bars indicate cultures that were not 
induced. Error bars denote the standard error. The strain expressing the BirA G154D and 
pCY730 grew very poorly and therefore was unavailable for  β-galactosidase assay 
(panels G and K). 
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Figure 2.6. Transcriptional regulation of the biotin operon mediated by the 
chromosomal birA alleles in cultures grown with various biotin concentrations. All 
strains contained the chromosomal bioF::lacZY fusion and originally carried plasmid 
pCY255 encoding yeast Bpl1.  In panel A the strains were grown in defined medium 
supplemented with various concentrations of biotin as shown on the X-axis. Grey bars 
denote wild-type birA allele, red bars denote the birA null (deletion) allele and the black 
bars the birA allele encoding BirA G154D. The results show the average of three 
independent experiments and the error bars denote the standard error. In panel B the 
growth of strain VC780 (chromosomal wild-type BirA) or strain VC779 (chromosomal 
BirA G154D) or their polA12 derivatives (strains VC801 and VC802, respectively). The 
strains were streaked on defined medium plates supplemented with 4 nM biotin and X-
gal that were incubated overnight at either 30°C or 42°C. The A and B designations of 
strains VC801 and VC802 denote two different transductants from the polA12 strain 
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Figure 2.6. (cont.)  
constructions. Strains VC780 and VC801 were derepressed (blue colonies) and grew at 
both temperatures due to the expression of wild-type BirA.  Strain VC779 grew at both 
temperatures due to the presence of pCY255 whereas strain VC802 failed to grow at 
42°C because pCY255 could no longer replicate due to loss of DNA polymerase I 
activity at the non-permissive temperature and strain VC779 grew at 42°C but remained 
repressed. 
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Figure 2.7. SDS-gel analysis of purified BirA and AccB-87 proteins along with the 
mass spectrometric analysis of biotinylated AccB-87 protein. In Panel A, the BirA 
proteins were subjected to electrophoresis in a 12% polyacrylamide gel whereas in Panel 
B the gel used for AccB-87 was 15%. BirA G154D consistently migrates more slowly 
than the other BirA proteins, a behavior that has been observed with other single amino 
acid substitutions (81).  In Panel C and D, the liquid chromatography-tandem mass 
spectrometric analysis of enzymatically biotinylated BCCP-87 peptides digested with V8 
(Endoproteinase Glu-C). Panel A: Biotinylation of K122 detected. The theoretical 
peptides are shown with K122 in bold and underlined. Ions score is −10 log(P), where P 
is the probability that the observed match is a random event. On average, individual ions 
scores > 46 indicate identity or extensive homology (p<0.05). In Panel B: Sequence 
coverage of BCCP87. Matched peptides are shown in bold red. 	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Figure 2.8. DNA binding properties of wild-type and mutant BirA proteins assayed 
by EMSA. In Panel A the ligase proteins purified as described in the Materials and 
Methods were tested for the presence or absence of biotin in the active site. The (+) 
symbol represents the addition of one of the ligands (biotin or ATP) whereas the (-) 
symbol indicates that the ligand was not added to the binding reaction. In Panels B, C, D 
and E the point mutant derivatives and wild-type BirA were assayed for binding to a 112-
bp bioO duplex DNA labeled at the 5'-ends with 32P prepared as described in Materials 
and Methods. The reaction products were separated via native gels electrophoresis and 
visualized via phosphorimagery. The mutant and wild-type BirA proteins (0-500 nM) 
were assayed in parallel. Reaction products were separated via native electrophoresis and 
visualized via phosphorimager. BirA mutants and wild-type BirA (0-500 nM) were 
subject to the same analysis. In panels (B, C, D and E) from left to right the BirA 
concentrations assayed were: 500 nM, 250 nM, 125 nM, 61.5 nM and 31.25 nM.   
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Figure 2.8. (cont.)  
Each panel contains the wild-type BirA plus a mutant BirA as given. The control 
reactions of all the panels are: NE no enzyme added. Panels B, C, D and E respectively, 
contained the G154D, K267M, I187T and M310L BirA proteins. 
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Figure 2.9. Abilities of the wild-type and mutant BirA proteins to synthesize 
biotinoyl-adenylate and transfer the biotin moiety to AccB-87.  In Panels A and B 
synthesis of the biotinoyl-adenylate in reaction mixtures containing BirA  (1 µM), biotin 
(0.01 mM) and [α-32P] ATP (0.1 µM) is shown. Following a 30 min incubation each 
reaction mixture was split into halves and to one half (+ symbols) purified apo-AccB-87 
(70 µM) was added followed by incubation for an additional 15 min whereas the other 
half (- symbols) were left untreated. One µl of each sample was then spotted onto a 
cellulose thin layer chromatography plate. Following plate development the reaction 
products (indicated by arrows), biotinoyl-adenylate (bio-5'-AMP) and AMP were 
visualized by autoradiography. In Panel B similar experiments were carried out except 
that two different concentrations of AccB-87 (7 µM or 70 µM) were used in the transfer 
assay. The control reactions of both panels are: NB, no biotin added and NE no enzyme 
added. The major spot on all lanes is ATP. The symbols (+) represent assays in which the 
acceptor AccB-87 was added whereas the symbol (-) denote assays in which the acceptor 
protein was not added.  
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Figure 2.10. The three-dimensional structure of BirA. In panel A the three different 
domains of the monomeric protein are shown. The single amino acid substitutions that 
resulted in superrepressor phenotypes are highlighted.  In panel B the 2.8 Å crystal 
structure of dimeric BirA complexed to the co-repressor analogue, biotinol-5'-AMP 
(colored white), is shown. Relative to the unliganded structure co-repressor analogue 
binding resulted in ordering of both adenylate-binding loops and the dimer interface also 
undergoes a favorable transition that might be necessary for BirA binding to bioO. 
Several of the mutations are found within the dimer interface, suggesting that they might 
stabilize the dimer to give the observed superrepressor phenotypes. The model was 
generated using the graphics program Chimera (86) with Protein Data Bank files 1HXD 
and 2EWN.  
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CHAPTER 3 
 
THE WING OF A WINGED HELIX-TURN-HELIX TRANSCRIPTION FACTOR 
ORGANIZES THE ACTIVE SITE OF BIRA, A BIFUNCTIONAL 
REPRESSOR/LIGASE 
3.1 INTRODUCTION 
The N-terminal truncation mutant discussed in Chapter 1 and the superrepressor 
mutants characterized in Chapter 2 strongly suggested that BirA coordinates its 
regulatory and enzymatic functions by communication between the ligase active site and 
the seemingly distant N-terminal domain. The mechanism of this communication has 
remained unknown. In this chapter I report that this communication is mediated by a 
small structure of the protein, the 14-residue wing of the wHTH structure (Figure 3.1).  
More specifically, I address the function of the wing motif in DNA binding and ligase 
activity. Despite many attempts by us and other workers, no crystal structure of BirA 
complexed with its operator is available, and therefore the role of the wing in DNA 
binding is based only on in vitro studies that show mutual protection of the wing and 
operator DNA from chemical attack (103, 104). I report that deletion of the wing or its 
substitution with the wing of an unrelated transcription factor results in loss of DNA 
binding. Strikingly, the wing deletion protein is deficient in ligase activity, but ligase 
function is largely restored by insertion of the foreign wing. Moreover, a superrepressor 
mutation in the BirA wing suppresses the phenotypes of mutations in the biotin-binding 
loop of the ligase catalytic site. These and other data indicate that the wing organizes the 
ligase active site in the absence of DNA binding.	  
3.2 MATERIALS AND METHODS 
Chemicals and culture media. The medium used in the physiological experiments was 
LB or 2XYT as the rich medium, whereas the defined medium was M9 salts 
supplemented with 0.4% glucose (or another carbon source as stated) and 0.1% Vitamin-
Free Casamino acids (Difco) (71). The antibiotics were used at the following 
concentrations: 100 µg/mL sodium ampicillin (Amp), 50 µg/mL kanamycin sulfate (Km), 
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25 µg/mL chloramphenicol (Cml), 12 µg/mL tetracycline HCl (Tet), and 50 µg/mL 
spectinomycin sulfate (Spec). The 15:1 mixture of ticarcillin disodium salt and potassium 
clavulanate (Research Products International) was used at 25 µg/mL. Integrated DNA 
Technologies provided oligonucleotides. PCR amplification was performed using Taq 
polymerase (New England BioLabs) and Pfu polymerase (Stratagene) according to the 
manufacturer’s specifications. DNA constructs were sequenced by ACGT, Inc. All 
reagents and biochemicals were obtained from Sigma-Aldrich and Fisher, unless 
otherwise noted. New England BioLabs supplied restriction enzymes and T4 DNA ligase, 
NaF, and Na3VO4. Invitrogen provided SYBER Green I nucleic acid gel stain and the 6% 
DNA retardation Novex TBE gels. PerkinElmer Life Sciences provided [α-32P] ATP 
(3,000 Ci/mmol). Analtech TLC uniplates of microcrystalline cellulose matrix were 
provided by Sigma-Aldrich. 
Bacterial strains and plasmids. All bacterial strains were derivatives of E. coli K-12 
(Table 3.1). Bacterial cultures were grown in shake flasks at 37°C, and growth was 
measured by absorbance at 600 nm using a Beckman DU600 spectrophotometer unless 
otherwise indicated. The E. coli B strain, BL21 (λDE3) strain was used for protein 
expression. Strain VC926 was constructed by transducing the ΔbirA::km deletion mutant 
from strain VC156 by P1 phage transduction into BL21(λDE3) carrying the birA plasmid 
pVC33. The strain was maintained on LB medium supplemented with 400 nM biotin. 
Other DNA manipulations were carried out by standard procedures. 
Plasmid constructions. The various N-terminal deletions were constructed using 
naturally occurring restriction sites plus adaptor oligonucleotide cassettes (Table 3.2). 
The Beckett deletion (Δ2–65) was constructed from the plasmid of Xu and Beckett (120). 
The truncated BirA coding sequence was moved into plasmid pBR329 using the EcoRI 
and HindIII sites of the donor and vector. A cassette made by annealing oligonucleotides 
dBeck-T and dBeck-B (Table 3.2) was then ligated between the EcoRI and PvuII sites to 
give an initiation codon PciI site and inactivate the EcoRI site. This modified coding 
sequence was then moved into pCY374 as described below. The Maeda deletion (Δ2–63) 
was made by the same manipulations using dMaed-T and dMaed-B to give a BspHI site 
at the initiation codon. The other deletions (Figure 3.2A) were constructed in a plasmid 
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made for another purpose by first inserting the BspHI-BssHII fragment of pBA11 into 
pMTL22P cut with NcoI and MluI. This plasmid was digested with XhoI (a unique site 
located upstream of the initiation codon) and AlwNI and ligated to an oligonucleotide 
cassette that preserved the wild-type amino acid sequence plus the XhoI and AlwnI sites, 
restored the BspHI initiation codon site, and introduced a KpnI site overlapping codons 
26 and 27 to give pCY771. To make the Δ3–25 deletion, plasmid CY771 was digested 
with XhoI and KpnI and ligated to an annealed cassette of birA-KT and birA-KB that 
inactivated the XhoI site and preserved the KpnI and BspHI sites. The Δ3– 60 deletion 
was made by the same manipulations except that the downstream site was the naturally 
occurring Bpu10I site, and the cassette consisted of birA-BT and birA-BB. The Δ3–40 
deletion was made by the same manipulations except that the downstream site was the 
naturally occurring AlwNI site, and the cassette consisted of birA-AT and birA-AB. 
Finally, the Δwing deletion (Δ48–61) was made by ligating an annealed ΔWT and ΔWB 
cassette between the AlwNI and Bpu10I sites of an intermediate birA plasmid chosen for 
the lack of complicating vector restriction sites. Each of the deleted birA genes was 
inserted into pCY374 digested with BspHI and NgoMIV and ligated to the BspHI (or PciI 
depending on the construct) plus NgoMIV fragments encoding the various deletion 
alleles (which replaced the wild-type birA gene of pCY374). Plasmid pCY374 is a 
derivative of pBA11 (11) that lacks the BspHI site downstream of the birA gene caused 
by digestion with NgoMIV and ligation under dilute conditions to delete a 528-bp 
fragment derived from the remains of tetracycline resistance gene of vector pACYC184. 
 For construction of the plasmid encoding BirA with the wing chimera, first the 
pVC26 fragment encoding the chimera was obtained using the DraIII and BstXI and 
ligated to plasmid pCY216 (30) digested with the same enzymes to give plasmid pVC27. 
Using primers VCC65 and VCC66 (Table 3.2), the region encoding the chimera wing 
was PCR- amplified to give a 598-bp DNA fragment. This fragment was then digested 
with PvuI and DraIII, gel-purified, and ligated to plasmid pBA11 digested with the same 
enzymes to give pVC28. Plasmids encoding the C-terminal hexahistidine-tagged 
derivatives of the chimera, Δ2–65 BirA, and Δwing BirA proteins were constructed by 
amplifying the BirA coding sequences from the pBA11 derivatives using primers VCC67 
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(or primer VCC60 for Δ2–65 BirA) and VCB17. The fragments were gel-purified, 
digested with BspHI (or PciI for Δ2–65 BirA) and BamHI, and ligated to pET19b cut 
with NcoI and BamHI. The BirAG57S and T52S derivatives were made using plasmid 
pVC10 as template and primers VCC23-VCC24 and VCB77- VCB78, respectively. All 
plasmids constructed were verified by restriction digestion followed by DNA sequencing. 
 The 10b strain is a BirA superrepressor mutant strain isolated in the selection and 
screening approach previously reported (25). The initial isolate encoded a protein with 
three amino acid substitutions (T52S, G115S, and Q75R). The effects of these mutations 
were deconvoluted by construction of plasmids carrying each mutation separately plus all 
pairwise double mutant derivatives by site-directed mutagenesis (Table 3.2). To construct 
the expression plasmid encoding a C-terminal hexahistidine-tagged version of the strain, 
10b-derived BirA mutant protein was amplified from the plasmid pVC46 using primers 
VCB16 and VCB17 (25), which added NcoI and BamHI sites as well as the purification 
tag. The digested products were ligated into the same sites of plasmid pET19b, to give 
plasmid pVC48. Plasmid VC48 was then digested with NcoI, treated with mung bean 
nuclease to generate blunt ends, and ligated to give plasmid pVC49. Plasmid VC47 was 
constructed by DraIII and PvuI digestion of pVC46. The 574-bp fragment encoding the 
mutations T52S, G115S, and Q75R was then inserted into plasmid pBA11 digested with 
the same enzymes. All of the plasmid constructs were confirmed by sequence analysis. 
 Plasmids VC37, 38, and 39 were constructed by site-directed mutagenesis 
(Stratagene QuikChange II protocol) using the following primer pairs (Table 3.2): 
VCB79-VCB80, VCC75-VCC76, and VCC77-VCC78, respectively, and pVC50 as the 
template. The template plasmids were digested with DpnI prior to transformation of 
strain DH5. All the mutations were confirmed by sequence analysis. The plasmids 
encoding the T52S mutant and the additional mutation at the biotin-binding loop were 
then digested with PvuI and DraIII and ligated into pBA11 digested with the same 
enzyme. The plasmids encoding BirA having single amino acid mutations were generated 
using site-directed mutagenesis using the primers in (Table 3.2) and pBA11 as the 
template. 
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In vivo complementation. Strain VC618 was transformed with the plasmid pBA11, 
pVC28, pVC29, pCY910, pCY895, pCY911, pCY897, pCY896, and pCY909, and the 
transformants were selected for on LB plates supplemented with ampicillin and 
chloramphenicol at 30°C. The temperature-sensitive plasmid pVC18 was cured from 
these strains by growth at 42°C on defined media supplemented with chloramphenicol. 
The loss of the temperature-sensitive plasmid was confirmed by ampicillin sensitivity. 
These strains were then used to carry out growth curve analyses as previously described 
(25). 
β-Galactosidase assays. The cultures were grown overnight and then diluted 1:400 into 
fresh medium of the same composition and grown to the early to mid-log phase before 
assays were performed. β-Galactosidase activity was determined as described (71) 
following disruption of the cells by sodium dodecyl sulfate-chloroform treatment. The 
data collected were from a minimum of three independent experiments. 
Protein purification. Expression, purification, and quantitation of the truncated AccB 
(AccB-87) apo acceptor protein was performed as previously described (25). The BirA 
plasmids encoding the wild-type, BirA10b mutant, BirA Δ2–65, chimera, G57S, and 
T52S proteins were purified from 1-liter LB cultures. The BL21 (λDE3) strains 
containing plasmids encoding the wild-type BirA, the 10b mutant protein, chimera, 
G57S, or T52S BirA were grown to an A600 0.8 at 37 °C, and T7 RNA polymerase 
expression was induced by the addition of 1 mM isopropyl β-D-thiogalactopyranoside for 
4 h at 30 °C. For the strain carrying the Δ2–65 BirA plasmid, the culture was grown at 30 
°C, and T7 RNA polymerase expression was induced by adding 100 µM isopropyl β-D-
thiogalactopyranoside and growing the culture for 4 h at 16 °C. The cells were harvested 
by centrifugation and stored at -80 °C. Cell lysis and protein purification were performed 
by the previously described protocols (25) with the following modification. Following the 
nickel affinity chromatography, the pooled fractions containing the BirA protein were 
dialyzed overnight in 50 mM sodium phosphate buffer (pH 8) containing 10% glycerol 
(Buffer A). The dialyzed sample was subjected to anion exchange chromatography using 
a Vivapure IEX Q Maxi H spin column. The column was equilibrated with buffer A prior 
to loading the dialyzed sample. The column was successively washed with the above 
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buffer, and the eluate was collected. The BirA proteins eluted in the flow through and the 
first wash steps, whereas the impurities bound to the column and only eluted with sodium 
phosphate buffer containing 2 M NaCl. The eluates were dialyzed against storage buffer 
(50 mM Tris-HCl, pH 8.0, containing 150 mM KCl, 10% glycerol, and 0.1 mM DTT) 
overnight, concentrated using Millipore concentrators, flash frozen, and stored at -80 °C. 
All the protein samples were found to be 95% pure except for Δ2– 65 BirA, which was 
found to be 80% pure by using 12% SDS-PAGE gels. 
 To purify the BirA Δwing protein strain, VC926 lacking the chromosomal birA 
gene was used. The protein was purified as above with some modifications. The 
induction medium and temperature were optimized to increase solubility of the protein. 
Rather than growing cultures in grown in LB with induction at 37 °C, which caused the 
protein to form inclusion bodies, the strain was grown in 1 liter of 2XYT medium 
buffered with M9 salts and supplemented with 400 nM biotin plus the ticarcillin-
clavulanate mixture. The cultures were grown at 30 °C to an A600 of 1.4, at which point 
T7 RNA polymerase expression was induced by the addition of 1 mM isopropyl β-D- 
thiogalactopyranoside for 3 h at 16 °C. The cells were then harvested and stored at -80 
°C. The lysate and protein purification was achieved using the protocol mentioned above. 
After nickel affinity purification, the protein was found to be 70% pure, judged by 
running the sample on a 12% SDS-PAGE gels. The protein was dialyzed into storage 
buffer, flash frozen, and stored at -80 °C. Attempts to further purify the protein using 
chromatography on ion exchange, Blue Sepharose affinity, HiTrap phenyl-HP 
hydrophobic, or size exclusion columns were fruitless. The Δwing BirA protein was 
found to be quite unstable in that it either precipitated on all the columns tested or eluted 
together with impurities (as in the case of the size exclusion chromatography). 
Bio-5ʹ′-AMP synthesis reactions. The assay for BirA-catalyzed in vitro protein 
biotinylation activity was performed as described previously (25) with some 
modifications. Protein concentrations were determined using the extinction coefficients 
calculated from the protein sequence using ExPASY Tools website. The assays contained 
50 mM Tris-HCl (pH 8), 5 mM tris- (2-carboxyethyl) phosphine, 5 mM MgCl2, 20 µM 
biotin, 5 µM ATP plus 16.5nM [α-32P] ATP, 100 mM KCl, and 1 µM BirA protein. Each 
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of the reaction mixtures were incubated at 37 °C for 30 min. For each BirA protein 
tested, two identical tubes were used, and at the end of 30 min, AccB-87 (50 µM) was 
added to one of each pair of tubes, whereas the other tube was left untreated. The tubes 
were incubated for an additional 15 min at 37 °C. One µl of each reaction mixture was 
applied to a cellulose thin layer chromatography plate of microcrystalline cellulose, and 
the plates were developed in isobutyric acid-NH4OH-water (66:1:33) (89). The thin layer 
chromatograms were dried for 10 h, exposed to a phosphorimaging plate, and visualized 
using a Fujifilm FLA-3000 Phosphor Imager and Fujifilm Image Gauge software 
(version 3.4 for Mac OS). To preclude the possibility of contaminating ATPase activity, 
different concentrations of sodium fluoride (50, 25, 10, or 5 mM) or Na3VO4 (10, 5, 2.5 
or 1 mM) were added either separately or together to the biotinylation reaction mixtures 
containing the wild-type BirA or Δwing BirA proteins. 
Electrophoretic mobility shift assays. To assay the DNA binding ability of the mutant 
BirA proteins and the wild-type protein, the method used is similar to the previously 
published protocol (25). A 112-bp DNA containing the biotin operator was PCR-
amplified using primers VCB36 and VCB37 and Taq DNA polymerase. The resulting 
PCR product was checked for size and quality on a 2% agarose gel. The DNA was then 
extracted from the gel using the Qiagen gel extraction kit. The DNA was quantitated 
using a Nanodrop spectrophotometer (Thermo Pierce). The DNA probe (40 nM) was 
incubated with varying concentrations of the BirA protein in binding buffer (50 mM Tris 
HCl, pH 8.0, 50 mM NaCl, and 10% glycerol) together with 50 µM biotin, 1 mM ATP, 5 
mM MgCl2, 100 mM KCl, and 5 mM tris-(2-carboxyethyl) phosphine at 37 °C for 30 
min. The products were then separated on a 6% DNA retardation gel and run for 1 h at 
100 V and 20 milliamps. The gel was then stained in 1X SYBR Green I nucleic acid gel 
stain solution made according to the manufacturer’s protocol. The gel was then visualized 
using Bio-Rad Chemi Doc XRS and Quantity One software. 
Bioinformatics and secondary structure analyses. The structural data for the proteins 
comparison were entered into Chimera program (86) along with the N-terminal region of 
BirA (Protein Data Bank code 1HXD). Using the Match Align tool, the alignment data 
were collected based on the secondary structure. The amino acid sequences for the 
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aligned proteins were then trimmed based on the secondary structure alignment. Each 
sequence was then entered into Clustal Omega program. The Clustal data were then 
entered into the ESPRIPT 2.2 program. The structural data from IHXD was used as the 
reference structure, and similarity settings were set so as to calculate the percentage of 
equivalent residues calculated per columns, considering their physicochemical properties. 
3.3 RESULTS 
N-terminal deletion mutants of BirA. The original N-terminal deletion protein, Δ2–65, 
had the expected defect in DNA binding (120) and retained in vitro catalytic activity, 
although it was severely defective in binding both biotin and biotinoyl-AMP (11). 
However, another group subsequently reported a similar N-terminal deletion, Δ2-63, and 
found the truncated protein to be functional in vivo (12). To address this apparent 
contradiction and because the Δ2–65 had not been tested in vivo, Dr. Cronan constructed 
genes encoding these two mutant proteins and several proteins having smaller N-terminal 
deletions, Δ3–25, Δ3–40, and Δ3–60 with various end points within the wHTH motif 
(Figure 3.2A). In the smallest of these deletions (called Δwing), only the 14-residue wing 
sequence of the wHTH motif was deleted. Each of these constructs was used to replace 
the birA gene in the medium copy number plasmid pBA11 (or a pBA11 derivative 
lacking an irrelevant vector sequence), in which a constitutive promoter drives birA 
expression. 
To determine the effects of these deletions on the regulation of the biotin operon 
and the in vivo ligation abilities of the mutant BirA proteins, each of the plasmids 
encoding an N-terminally truncated protein was transformed into strain VC618 
(ΔbirA::kan bioF::lacZY ΔlacZY/pVC18) at 30°C. Expression of LacZ (β-galactosidase) 
provides an assay for transcription of the bioBFCD operon (12). As mentioned above 
(Chapter 2), the strain VC618 is a biotin auxotroph caused by the lacZY insertion into the 
bio operon and lacks birA because of deletion of the entire gene. Because birA is essential 
for growth, this strain survives because of expression of the yeast Bpl1 ligase (38) from a 
plasmid (pVC18) that is temperature-sensitive for replication (25). Following 
transformation with the plasmids to be tested, the transformants were cured of the Bpl1 
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ligase plasmid by growth at 42°C. The cured strains producing the various mutant 
proteins were plated on MacConkey indicator plates that contained a repressing biotin 
concentration (115 nM biotin) or lacked biotin supplementation (the medium contains 
about 15 nM biotin). A strain expressing wild-type BirA gives white colonies on 115 nM 
biotin and red colonies on 15 nM biotin (red colonies are due to high level lactose 
utilization, the acidic products of which react with indicator dyes in the medium). In 
contrast, the strains expressing the N-terminal deletion mutants gave red colonies on both 
the 115 and 15 nM biotin plates, indicating that the mutant proteins were deficient in bio 
operon regulation. That is, a normally repressing biotin concentration failed to repress. 
To quantify these results, β-galactosidase levels were assayed on the strains after growth 
in minimal media supplemented with biotin concentrations that were either strongly 
repressing (10 µM) or depressing (10 nM) (Figure 3.2B). The strain expressing wild-type 
BirA was strongly repressed at the higher biotin concentration and showed an ~14-fold 
greater activity at the lower biotin concentration, whereas the strains expressing the N-
terminal deletion proteins had essentially the same activities at both biotin concentrations. 
Moreover, when grown with 10 µM biotin, the deletion mutant strains had activities 100-
fold greater than the strain expressing wild-type BirA, indicating that the mutant proteins 
were completely unable to repress bio operon expression. 
 The finding that the strains expressing the N-terminal deletion proteins survived 
loss of the yeast Bpl1 plasmid argued that they retained at least a minimal level of ligase 
activity. To test this indication, I grew the strains in minimal media containing various 
levels of biotin (Figure 3.3). All of the mutant strains grew normally on 40 nM or 4 µM 
biotin but grew more slowly than the wild-type strain on 4 nM biotin, and growth was 
especially slow with 1.6 nM biotin. Therefore, the defects in biotin and biotinoyl-AMP 
demonstrated in vitro for the Δ2–65 protein by Xu and Beckett (120) can be overcome by 
high extracellular biotin concentrations, and the protein biotinylation proficiency of the 
Δ2–63 protein reported by Maeda and co-workers (70) can be ascribed to high level 
biotin production by their host strain and the high biotin concentration used in their in 
vitro experiments (10 µM). Hence, there seems to be no contradiction between the two 
reports. 
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Insertion of a nearly isosteric foreign wing largely restores in vivo biotinylation 
ability to the Δwing BirA. The wing structures of wHTH proteins often aid HTH DNA 
binding by making contacts in the DNA minor groove (17); therefore it was not 
surprising that the Δwing BirA protein was defective in regulation of bio operon 
expression. However, an unexpected finding was that the small 14-residue deletion 
protein was as compromised in the ability to support growth at low biotin concentrations, 
as were the proteins with much larger deletions (Figure 3.3). These results argued that the 
wing is required for full biotin ligase activity and might play a structural role or 
contribute residue side chains involved in catalysis. To test these possibilities, I searched 
the protein structure databases for wHTH wings that closely resembled the BirA wing 
(Figure 3.4C). The BirA wing is small, which limited the possibilities, but one protein, 
OmpR, has a wing that is a very close match to the BirA wing (Figure 3.4A and 3.4B). 
Unlike BirA, the wHTH structure is located at the C-terminus of OmpR, a transcriptional 
regulator of E. coli outer membrane permeability. Given the close match of the two 
structures, I substituted the OmpR wing for that of BirA and found that expression of this 
chimera protein allowed almost normal growth at the low biotin concentrations where the 
Δwing protein functioned poorly (Figure 3.3). Hence, the wing structure rather than its 
exact sequence is required for normal ligase activity. 
The chimera protein remained defective in bio operon regulation, indicating that 
the role of the BirA wing in DNA binding is specific. However, five of the ten wing 
residues are conserved between the BirA and OmpR wings (Figure 3.4A). To test 
whether one of these residues played an important role in wing function, I altered each of 
these BirA residues in turn, often to residues that were reported to alter DNA binding by 
OmpR (Table 3.3) (60). All of these single residue substitutions within the wing resulted 
in normal growth on 1.6 nM biotin as seen for the T52S mutant protein (Figure 3.3), and 
thus it seemed likely that the structure rather than the sequence of the wing is the 
important factor in ligase activity. Moreover, only those BirA proteins having 
substitutions of BirA residues Gly-57 and Tyr-58 (G57S and Y58F, respectively), both of 
which are conserved in the OmpR wing, were defective in transcriptional repression 
(Figure 3.2B). In the latter case, the tyrosine hydroxyl group seems to be the important 
functional group because the Y58T BirA had bio operon repressor function (data not 
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shown). I also studied a wing mutant, T52S, that was serendipitously isolated in our prior 
search for superrepressor BirA mutants (25) and found it showed a 5-fold increase in 
repression at 10 nM biotin relative to wild-type BirA, whereas at a higher biotin 
concentration (10 µM), its repression ability was indistinguishable from that of wild-type 
BirA (Figure 3.2B). In OmpR, it was reported that substitution of isoleucine for the 
OmpR Thr-224, a wing residue analogous to Thr-52 of BirA, resulted in a protein 
defective in DNA binding (60), and thus I made the same substitution in BirA and found 
the T52I BirA protein had normal repression ability (data not shown). Hence, although 
the OmpR and BirA wings show strong structural conservation (Figure 3.4B), the 
residues conserved between the two proteins have different functions. 
In vitro studies of the BirA point mutant, Δwing, and chimera proteins. The in vitro 
studies omitted the proteins having large N-terminal deletions because their in vivo 
properties were very similar to those of the Δ2–65 deletion protein of Xu and Beckett 
(120), which have been thoroughly studied in vitro. I purified the C-terminal 
hexahistidine-tagged BirA chimera, BirA Δwing, BirA Δ2–65, BirAG57S, BirAT52S, 
and wild-type proteins all to apparent homogeneity with the exception of the BirA Δwing 
and BirA Δ2– 65 proteins, which were recalcitrant to purification of about 80% purity 
(Figure 3.5A). I first tested the DNA binding abilities of the purified BirA proteins by 
electromobility shift assays using a 112-bp biotin operator. 
 The Δwing and the G57S BirA proteins showed no DNA binding even at the 
highest protein concentrations tested (Figure 3.5B). Higher concentrations of the Δwing 
protein could not be tested because of its precipitation and clogging of the wells. The 
chimera protein gave a weak but detectable shift (Figure 3.5B). However, the shift 
differed from that seen with the wild-type protein. To test whether this shift represented a 
nonspecific interaction, I carried out a similar mobility shift experiment using a 117-bp 
XmnI-ScaI DNA fragment of vector pUC19 in place of the operator sequence. The 
chimera protein shifted this fragment, and thus the protein seems able to bind DNA, but 
without sequence specificity (data not shown). 
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 The T52S BirA showed increased ability to bind the bio operator (Figure 3.5C and 
D), consistent with its in vivo behavior (Figure 3.2B). At BirA concentrations of 250 nM, 
the T52S protein bound 90% of the operator DNA compared with 75% binding by the 
wild-type BirA protein (Figure 3.5D). Moreover, significant DNA binding was observed 
at 62.5 nM BirA for T52S BirA whereas, wild-type protein showed only barely 
detectable binding (Figure 3.5C and D). In past work, I have seen a significant variation 
in binding by wild-type BirA (25), and therefore I conducted these studies over a range of 
concentrations and assayed the mutant protein in parallel with the wild-type protein. I 
found that the T52S mutant invariably exhibited a higher extent of DNA binding than the 
wild-type protein (Figure 3.5D). 
 I also tested the abilities of the purified proteins to synthesize Bio-5ʹ′-AMP in the 
first ligase partial reaction and to transfer the biotin moiety to the AccB-87 acceptor 
protein in the second partial reaction (Figure 3.6). Because Bio-5ʹ′-AMP is required for 
DNA binding, an inability to synthesize the ligand would be manifested as a defect in 
operator binding. I tested the purified BirA proteins for the ability to synthesize Bio-5ʹ′-
AMP from biotin and [α-32P] ATP. All of the mutant proteins synthesized Bio-5ʹ′-AMP 
(Figure 3.6), and thus the ligand required for DNA binding was present in the gel shift 
experiments. However, a striking result was seen in the reactions containing the Δwing 
protein. This protein converted ATP to ADP, an off target reaction in which the incorrect 
phosphoric anhydride linkage was cleaved. This off target product can be attributed to 
loss of the wing because it was not seen in reactions containing the chimera protein or 
any other protein. However, it remained possible that the Δwing protein preparations 
were contaminated with a co-purifying ATPase activity. To test this possibility, I added 
two general inhibitors of ATPase activity, 25 mM NaF and 5 mM Na3VO4, either 
separately or together, to reactions containing the Δwing BirA and found no significant 
decrease in ADP production in the presence of the inhibitors (Figure 3.7). Hence, ADP 
production is a property of the Δwing protein. 
 I tested the activities of these proteins in the second partial reaction of BirA: 
transfer of the biotin moiety to the AccB-87 acceptor protein. Each of Bio-5ʹ′-AMP 
synthesis reactions was run in duplicate and incubated to allow accumulation of Bio-5ʹ′-
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AMP. AccB-87 was added to one of the duplicate tubes followed by further incubation 
and chromatography (Figure 3.6). Transfer of the biotin moiety to AccB-87 results in 
disappearance of the Bio-5ʹ′-AMP spot and strong augmentation of the AMP spot (25). 
Each of the mutant proteins showed this behavior, although the Δwing protein appeared 
somewhat deficient in transfer (Figure 3.6). 
Genetic evidence for direct interaction of the wing with the ligase active site. The 
birA gene was originally defined by a single mutant allele, birA1 (21). This mutation 
encoded a G115S substitution within a highly conserved BPL motif that resulted in a loss 
of the ability to repress bio operon expression and an inability to grow at low biotin 
concentrations (12),(19). This protein was subsequently studied in vitro by Kwon and 
Beckett (64) and was found to be severely defective in binding both the biotin substrate 
and the Bio-5ʹ′-AMP intermediate, properties that readily explain the physiological 
deficiencies in repression and growth. This and neighboring residues defined the biotin-
binding loop that becomes structured upon binding biotin or Bio-5ʹ′-AMP (119). 
The T52S wing mutation discussed above was originally isolated in a triply mutant birA 
strain called 10b (25). In addition to the T52S alteration, the mutant gene of strain 10b 
encoded the G115S birA1 mutation plus a Q75R mutation (Table 3.2). Strikingly, the 
triply mutant protein strongly repressed bio operon transcription (Figure 3.7), despite the 
presence of the G115S mutation, which abolishes repression as the sole mutation (12). I 
deconvoluted the lesions of the triple mutant gene and found that upon removal of the 
T52S mutation, the encoded protein showed the lack of repression ability characteristic of 
the G115S BirA protein (Figure 3.8). Elimination of the G115S mutation had little or no 
effect on the proteins that retained the T52S mutation; both the T52S and T52S Q75R 
proteins repressed much more strongly than wild-type BirA (Figures 3.8 and 3.9). 
Finally, elimination of the Q75R mutation, leaving the T52S and G115S mutations intact, 
resulted in a protein that repressed bio operon expression as strongly as the original 
superrepressor strain, indicating that the Q75R mutation is silent (Figures 3.8 and 3.9). I 
also carried out in vitro biotinylation assays with the purified BirA10b mutant protein and 
found that the protein synthesized the Bio-5ʹ′-AMP ligase intermediate and transferred the  
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biotin moiety to the AccB-87 acceptor protein (Figure 3.6B). Hence, the T52S BirA not 
only binds operator DNA more tightly than the wild-type protein but also overcomes the 
ligation defect engendered by the G115S mutation. 
 Because the G115S mutation alters the BirA biotin-binding loop (117), two other 
repression-defective biotin-binding loop birA alleles isolated by Barker and Campbell 
(12), the protein products of which had been studied by Kwon and Beckett (64), were 
tested to ascertain whether the T52S mutation showed allele specificity. The R118G BirA 
is similar to the G115S BirA in that it also binds biotin and Bio-5ʹ′-AMP poorly, whereas 
the R119W BirA binds biotin and Bio-5ʹ′-AMP with essentially wild-type binding 
constants (64). I constructed plasmids encoding the R118G and R119W proteins and 
transformed the plasmids into strain VC618. After driving out the Bpl1 plasmid, I found 
that the strains grew with 4 nM biotin and were defective in repression of biotin operon 
transcription at 4 µM biotin. As in the case of the G115S protein, introduction of the 
T52S allele into the genes encoding the R118G and R119W proteins restored repression 
(Figure 3.9). Therefore, the ability of the T52S mutation to restore repression to 
otherwise repression-defective biotin-binding loop mutants is not restricted to G115S 
BirA. Note that our ability to grow strains encoding the G115S and R118G proteins in 
media containing 4 nM biotin is due to overproduction of the proteins, and hence our data 
do not conflict with those of Barker and Campbell (12), who assayed expression from the 
chromosomal locus. 
3.4 DISCUSSION 
 All of the birA deletion mutations lacked both repression activity and the ability to 
grow normally at low biotin concentrations (Figures 3.2 and 3.3) and thus were similar in 
phenotype to the original construct of Xu and Beckett (120), which had not previously 
been characterized in vivo. The growth defects of the various deletion mutants were only 
apparent at low biotin concentrations (Figure 3.3), whereas the repression defect was seen 
at all biotin concentrations (Figure 3.2). As mentioned above, the multiple BirA  
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structures available (unliganded or liganded with biotinoyl-lysine, biotin, or a Bio-5ʹ′-
AMP analog) fail to provide an explanation for the loss of ligase activity resulting from 
deletions within the N-terminal domain. 
 It was surprising to find that the Δwing BirA was as defective in growth and 
repression as the proteins with much larger deletions (Figures 3.2 and 3.3). To test the 
role of the wing in BirA ligase activity and repressor function, I replaced the BirA wing 
with the foreign isosteric wing of OmpR. This replacement largely restored growth at low 
biotin concentrations to the Δwing protein (Figure 3.3), indicating that the wing structure 
must stabilize the enzyme active site and that the OmpR wing is a good mimic of the 
BirA wing. Both the chimera and Δwing BirAs were defective in repressor function, 
indicating that although half the residues are conserved between the BirA and OmpR 
wings (Figure 3.4A), the operative DNA contacts are not conserved. The chimera protein 
synthesized Bio-5ʹ′-AMP and biotinylated the AccB-87 acceptor protein (Figure 3.6). The 
Δwing BirA has a flawed active site as shown by hydrolysis of much of the ATP 
substrate to ADP, an off pathway product. The OmpR wing overcomes this problem 
further, indicating that the wing stabilizes and organizes the active site to allow both 
ligase partial reactions to proceed efficiently (Figure 3.6). 
 The importance of the BirA wing was strikingly demonstrated by a remarkable 
fortuitous intragenic epistasis (Figure 3.9). The protein carrying both the T52S 
superrepressor mutation and the G115S biotin-binding loop mutation has the phenotype 
of a superrepressor mutant rather than displaying the lack of repression and deficient 
ligase activity characteristic of the G115S BirA (64,11). Similar results were seen with 
two other biotin-binding loop mutants. These data strongly argue that when free in the 
cytosol, the wing contacts the flexible loop (residues 116–124) that becomes ordered in 
the presence of biotin and Bio-5ʹ′-AMP (103,119,122) and aids the ordering process. 
Proteins having amino acid residue substitutions within or adjacent to the loop have 
poorly ordered loops and therefore bind biotin and biotinoyl-AMP poorly; however, this 
is over-come when the wing carries the T52S mutation. These data together with the 
properties of the Δwing and chimera proteins indicate that Bio-5ʹ′-AMP synthesis would 
proceed only when BirA is free in the cytosol where the wing-biotin-binding loop 
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interaction can occur. When BirA is DNA-bound, the wing is removed from the biotin-
binding loop region, but this is of no consequence because, the loop is fully ordered; 
because of the binding of the Bio-5ʹ′-AMP required for dimerization and DNA binding. 
 To our knowledge, this is the first report that the wing of a wHTH protein 
determines the activity of an enzyme. This also may be the first case of a successful 
“wing swap” in a wHTH protein. Most members of the wHTH family use the wing to 
directly assist DNA binding, as is the case for BirA in its regulatory role. However, in the 
SOS response LexA repressor, the wing structures fulfill spacer length requirements such 
that the two DNA-binding domains of the dimeric protein are positioned to make specific 
contacts within the same minor groove of the SOS regulon operators (123). The wHTH 
of the plasmid stability protein TubR is involved in DNA binding, but in a very atypical 
manner. The TubR recognition helices mediate dimerization, thereby precluding 
canonical HTH-DNA interactions. Instead the two wing structures plus the N termini of 
the recognition helices mediate DNA binding by insertion into the same major groove 
(79). Other wHTH proteins have evolved to use the wing for more diverse purposes. For 
example, in the heat shock transcriptional factor, the wing plays a role in dimerization of 
the protein (67), whereas in DEAH helicases, the wHTH domain has also been implicated 
in opening double- stranded DNA and RNA molecules in an ATP-independent manner 
(107). Therefore, despite the structural conservation of wHTH motifs, no model protein-
DNA complex can be chosen to represent a paradigm for wHTH motif-containing 
proteins. Indeed, we probably have just scratched the surface of the diverse functions that 
this ancient and highly conserved motif might encompass. 
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3.5 TABLES AND FIGURES 
Table 3.1.  Bacterial strains and plasmids used in this chapter. 
Strain Relevant Genotype or Description 
Reference or 
Derivation 
MG1655 E. coli K-12 wild-type Lab collection 
BL21 (λDE3) ompT, hsdSB (rB–, mB–), dcm, gal, (λDE3) Novagen 
DH5α Δ(argF-lacZ)U169 glnV44 Φ80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
Lab collection 
VC618 VC537 birA::kmR (25) 
VC926 BL21 (λDE3) birA::kmR with pVC33  
Plasmids   
pBeckett pBTac1 encoding BirA65-321 (120) 
pBA11 plasmid pACYC184 encoding BirA (11) 
pCY255 plasmid encoding Bpl1 of S. cerevisiae (38) 
pCP20 Flp expression plasmid, AmpR, CmlR (40) 
pKD46 oriR101, red recombinase expression plasmid (40) 
pKD3 oriRγ template plasmid, CmlR (40) 
pKD4 oriRγ template plasmid, KmR (40) 
pET19b T7 promoter expression vector, AmpR Novagen 
pCY216 plasmid carries the birA gene under the control 
of araBAD promoter and araC gene 
(30) 
pVC7 pACYC184 encoding BirA; TetR (25) 
pVC10 pET19b encoding C-terminal hexahistidine 
tagged BirA, AmpR 
(25) 
pVC18 pEAK-1 encoding BPLI, AmpR (25) 
pVC19 pET16b encoding C-terminal BCCP, AmpR (25) 
pVC26 pIDT encoding the chimera BirA This study 
pVC27 pCY216 encoding chimera BirA This study 
pVC28 pBA11 encoding chimera BirA This study 
pVC29 pBA11_encoding T52S BirA This study 
pVC30 pBA11 encoding G57S BirA This study 
pVC31 pBA11_encoding Y58F BirA This study 
pCY910 pBA11 encoding Δ2-65 BirA This study 
pCY895 pBA11 encoding Δ3-40 BirA This study 
pCY911 pBA11 encoding Δ2-63 BirA This study 
pCY897 pBA11 encoding Δ3-25 BirA This study 
pCY896 pBA11 encoding Δ3-60 BirA This study 
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Table 3.1. (cont.) 
pCY909 pBA11 encoding Δwing BirA This study 
pVC32 pET19b encoding C-terminal hexahistidine 
tagged chimera BirA 
This study 
pVC33 pET19b encoding C-terminal hexahistidine 
tagged Δwing BirA 
This study 
pVC34 pET19b encoding C-terminal hexahistidine 
tagged  T52S BirA 
This study 
pVC35 pET19b encoding C-terminal hexahistidine 
tagged  G57S BirA 
This study 
pVC36 pET19b encoding C-terminal hexahistidine 
tagged Δ2-65 BirA 
This study 
pVC37 pVC7 encoding T52S and G115S BirA This study 
pVC38 pVC7 encoding T52S and R118G BirA This study 
pVC39 pVC7 encoding T52S and R119W BirA This study 
pVC40 pBA11 encoding G115S BirA This study 
pVC41 pBA11 encoding T52S and G115S BirA This study 
pVC42 pBA11 encoding  R118G BirA This study 
pVC43 pBA11 encoding  T52S and R118G BirA This study 
pVC44 pBA11 encoding R119W BirA This study 
pVC45 pBA11 encoding  T52S and R119W BirA This study 
pVC46 pVC7 encoding  T52S, Q75S and G115S BirA This study 
pVC47 pBA11 encoding  T52S, Q75S and G115S BirA This study 
pVC48 pET19b encoding C-terminal hexahistidine 
tagged T52S, Q75S and G115S BirA 
This study 
pVC49 Mung bean treated pVC48 This study 
pVC50 pVC7 encoding T52S BirA This study 
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Table 3.2. Oligonucleotide primers used in this chapter. 
Oligonucleotide Sequence 
VCB17_BamHI CGCGGATCCTTAATGATGATGATGATGATGTTTTTCTGC 
VCB77 T52S_F CTGGGGCGTTGATGTCTTTTCCGTTCCGGG 
VCB78 T52S_R CCCGGAACGGAAAAGACATCAACGCCCCAG 
VCB79 G115S_F GCAGAATACCAGCAGGCTAGCCGTGGTCG 
VCB80 G115S_R CGACCACGGCTAGCCTGCTGGTATTCTGC 
VCB36 GGCAAGATCGTCCGTTGTCATAATCGAC 
VCB37 GCCATGGGGCTTCTCCAAAACGTG 
VCC15 T52I_F CTGGGGCGTTGATGTCTTTATCGTTCCGGG 
VCC16 T52I_R CCCGGAACGATAAAGACATCAACGCCCCAG 
VCC17 G55S_F GATGTCTTTACCGTTCCGAGCAAAGGATACAGCCTGCC 
VCC18 G55S_R GGCAGGCTGTATCCTTTGCTCGGAACGGTAAAGACATC 
VCC19 V53A_F CGTTGATGTCTTTACCGCTCCGGGTAAAGGATAC 
VCC20 V53A_R GTATCCTTTACCCGGAGCGGTAAAGACATCAACG 
VCC21 V53M_F GGGCGTTGATGTCTTTACCATGCCGGGTAAAGGATACAG 
VCC22 V53M_R CTGTATCCTTTACCCGGCATGGTAAAGACATCAACGCCC 
VCC23 G57S_F 
GATGTCTTTACCGTTCCGGGTAAAAGCTACAGCCTGCCT
G 
VCC24 G57S_R 
CAGGCAGGCTGTAGCTTTTACCCGGAACGGTAAAGACAT
C 
VCC25 Y58F_F CCGTTCCGGGTAAAGGATTCAGCCTGCC 
VCC26 Y58F_R GGCAGGCTGAATCCTTTACCCGGAACGG 
VCC27 Y58T_F CGTTCCGGGTAAAGGAACCAGCCTGCCTGAGCC 
VCC28 Y58T_R GGCTCAGGCAGGCTGGTTCCTTTACCCGGAACG 
VCC60Beck_PciI CGCGACATGTTACTTAATGCTAAACAGATATTGG 
VCC65_DraIII CATTCAGACACTGCGTGACTGGGGCG 	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Table 3.2. (cont.) 
VCC66_PvuI CGTATTACGATCGAGATTGATCCCCGCTTCCTGC 
VCC67_BsphI GCGGTCATGAAGGATAACACCGTGCCACTG 
VCC75 R118G_F GGCTGGCCGTGGTGGCCGGGG 
VCC76 R118G_R CCCCGGCCACCACGGCCAGCC 
VCC77 R119W_F GGCCGTGGTCGCTGGGGTCGGAAAT 
VCC78 R119W_R ATTTCCGACCCCAGCGACCACGGCC 
dBeck-T 
AATTGACATGTTACTTAATGCTAAACAGATATTGGGTCA
G 
dBeck-B CTGACCCAATATCTGTTTAGCATTAAGTAACATGTC 
dMaed-T AATTGTCATGATCCAGTTACTTAATGCTAAACAGATATT
GGGTCAG 
dMaed-B 
CTGACCCAATATCTGTTTAGCATTAAGTAACTGGATCAT
GAC 
birA-KT TCGAGAAGACTCATGAAGGGTAC 
birA-KB CCTTCATGAGTCTTC 
birA-BT TCGAGAAGACTCATGAAGCC 
birA-BB TCAGGCTTCATGAGTCTTC 
birA-AT TCGAGAAGACTCATGAAGCAAACA 
birA-AB ATGCTTCATGAGTCTTC 
∆WT TGCGTGACTGGGGCGC 
∆WB TCAGCGCCCCAGTCACGCAGTGT 
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Table 3.3. N-terminal deletion and point mutants of BirA plus OmpR mutants. 
 
Repression 
Biotin 
requirement 
(nM)a 
 
Mutation siteb 
 
Secondary 
structurec 
OmpR 
mutantd 
 
Reference 
+ 1.6 None   (12) 
++ 1.6 T52S Wing  This study 
+ 1.6 T52I Wing T224I This study 
+ 1.6 V53A Wing  This study 
+ 1.6 V53M Wing  This study 
+ 1.6 G55S Wing  This study 
- 1.6 G57S Wing G229S This study 
- 1.6 Y58F Wing  This study 
+ 1.6 Y58T Wing  This study 
- 41-4000 Δ2-65 wHTH  (120) 
- 41-4000 Δ2-63 wHTH  (70) 
- 41-4000 Δ3-60 wHTH  This study 
- 41-4000 Δ3-40 Helix I, II, II  This study 
- 41-4000 Δ3-25 Helix I, II  This study 
- 41-4000 Δ48-61 ΔWing  This study 
- 1.6 50-62 substitution Chimera  This study 
- 4000 G115S BBLe  (11);(21) 
- 41-4000 R118G BBL  (12) 
- 4 R119W BBL  (12) 
 
a The minimal biotin requirements of the deletion and the point mutants constructed in 
this study. The data for the N-terminal mutants are directly from (11, 12, 21). 
b Positions are amino acid residue positions. 
cLocations of the mutations in the secondary structure of BirA protein. 
dWing residue substitutions having regulatory effects in the OmpR system. 
eBBL, Biotin binding loop. 
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Figure 3.1.  The three-dimensional structure of monomeric BirA protein. Shows the 
BirA structure (Protein Data Bank 1HXD) in which the protein is complexed with biotin 
(119). The N and C termini are denoted by N and C, respectively. Note that some loops 
were not visible in the crystals because of their high mobility and are shown as breaks in 
the chain. 
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Figure 3.2. Properties of the wild-type, N-terminal deletion and point mutant BirA 
proteins. A, location of the mutants studied. The colored bars show the extents of the 
various deletions. The BirA residues have the same color code as the helix (the 
recognition helix is helix 3) except for the wing structure where the residues altered by 
point mutations are given in red type. B, expression of the bio operon in cultures grown 
with 10 nM biotin (derepression conditions; solid bars) or 10 µM (repression conditions; 
open bars) biotin assayed by use of β-galactosidase encoded by a chromosomal 
bioF::lacZY fusion. The strains used were derivatives of strain VC618 cured of plasmid 
pVC18 (25). Single colonies were streaked on defined medium plates supplemented with 
10 nM biotin and X-gal for phenotypic confirmation. Liquid cultures grown in the same 
medium lacking X-gal and were then assayed for bio operon transcription by β-
galactosidase activity (“Materials and Methods”). Note that the data are plotted on the y-
axis as a log scale. The results show the average of three independent experiments and 
the error bars denote the standard error. 
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Figure 3.3. Complementation of the E. coli ΔbirA::km bioF::lacZY strain by 
expression of wild-type BirA, BirA T52S mutant protein, and BirA N-terminal 
deletion mutant proteins. The strains were assayed for growth in defined medium liquid 
cultures supplemented with various concentrations of biotin as given by the colored 
symbols of the third row as described under “Materials and Methods.” Each of the panels 
is the host strain expressing a different birA allele. Each growth assay was carried out in 
triplicate, and this plot shows the averages of the triplicate cultures. Growth was 
measured by optical density at 600 nm. Note that the data are plotted on the y-axis as a 
log scale. All the panels share the same color code. Expression was driven by the 
constitutive promoter of a medium copy number plasmid. 
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Figure 3.4. Sequences and structural alignments of the DNA-binding domains of 
several wHTH regulatory proteins. A, alignment of the C-terminal DNA-binding 
domain of OmpR with the N-terminal BirA DNA-binding domain. B, superimposition of 
the OmpR DNA-binding domain on the BirA N-terminal domain. The model was made 
using the Match Align Tool of Chimera (86) with Protein Data Bank files 1HXD and 
1OPC. C, alignments of the wing motifs for several wHTH regulatory proteins of known 
structure were generated using the method described under “Materials and Methods.” The 
Protein Data Bank files used were: BirA, 1HXD; OmpR, 1OPC; Rap30, 1BBY; CRP, 
1CGP; FadR, 1E2X; PhoB, 1QQI; LexA, 1JHF; HNF-3γ, 1VTN; RFX1, 1DP7; and 
PcoR, 2JZY. Identical residues are denoted by white letters on a red background, similar 
residues are denoted by red letters on a white background, variable residues are in black 
letters, and dots represent gaps. In A and C, the alignment was generated using the BirA 
secondary structure as the reference structure. In A and C, the secondary structures of the 
proteins are shown at the top of the panel: β, β-sheets; β-coils, -turns; α, α-helices. In B, 
H1, H2, and H3 denote helices 1, 2, and 3, respectively. W denotes the wing structure, 
whereas α denotes the OmpR loop that interacts with RNA polymerase subunit α. Helix 
3 is the recognition helix. 
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Figure 3.5. Purification and operator binding of purified BirA proteins. A, the BirA 
and AccB-87 proteins were subjected to electrophoresis in a 12% polyacrylamide gel. 
The Precision Plus protein standards from Bio-Rad are shown in lane M, and AccB-87 is 
in the far right-hand lane. The proteins were purified as described under “Materials and 
Methods” and dialyzed in storage buffer prior to storage at -80 °C. In B, at 1 µM, the 
BirA mutant derivatives and wild-type BirA purified as described under “Materials and 
Methods” were assayed for binding to a 112-bp bioO duplex DNA prepared as described 
under “Materials and Methods.” The reaction products were separated by native gel 
electrophoresis, and the gels were stained with SYBR Green I nucleic acid gel stain and 
visualized using the Bio-Rad Chemi Doc XRS. In C, the point mutant T52S and wild-
type BirA proteins (0 –500 nM) were subjected to the same analysis. In D, the results 
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Figure 3.5. (cont.) 
from three independent experiments were quantified with the Quantity One program. % 
DNA bound represents the percentage of DNA bound to BirA protein versus the 
percentage of remaining unbound calculated for each lane using the no enzyme (NE) lane 
as control for the amount of DNA loaded. The results are presented as the averages and 
standard errors of triplicate determinations and the error bars denote the standard error. 
The open bars represent the wild-type BirA, and the closed bars represent the T52S 
mutant protein. The identities of the BirA proteins tested are given at the tops of A, B, 
and C. The standards in B and C are the 100-bp DNA ladder (Life Technologies).  
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Figure 3.6. Thin layer chromatographic analysis of various BirA proteins to 
synthesize Bio-5ʹ′-AMP and transfer the biotin moiety to AccB-87. Synthesis of 
biotinoyl-adenylate in reaction mixtures containing 1 µM BirA, 20 µM biotin, 5 µM 
ATP, 5 mM MgCl2, 100 mM KCl, 5 mM TCEP, and 16.5 nM [α-32P] ATP is shown. 
Each reaction was run in duplicate and incubated for 30 min at 37 °C, after which time 
point plus signs (+) purified apo-AccB-87 (50 µM) was added to one of the duplicate 
reactions followed by incubation for an additional 15 min. The second duplicate reaction 
did not receive AccB-87 (minus signs). One µl of each reaction was spotted onto a 
cellulose thin layer chromatography plate. The right panels with 10b BirA mutant show a 
separate experiment. Following plate development, the reaction products (indicated by 
arrows), biotinoyl-5ʹ′-AMP (Bio-5ʹ′-AMP), ADP, AMP, and the remaining ATP were 
visualized by autoradiography. NE denotes the control reactions lacking BirA. The 
proteins assayed are given at the top of the figure, and the identities of the spots are on 
the left margin. A and B show the products of the BirA reaction in the presence or 
absence of the AccB-87 acceptor protein. The identity of each protein is given at the top 
of each pair of lanes. The wild-type (WT) and Δwing proteins were included in both 
analyses as controls. 
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Figure 3.7. Thin layer chromatographic analysis of wild-type and Δwing BirA 
proteins to synthesize Bio-5ʹ′-AMP in the presence of ATPase inhibitors. In panel A 
and B synthesis of biotinoyl-adenylate were carried out for the wild-type BirA protein 
and the Δwing BirA protein in the presence of varying concentration of sodium fluoride 
and Na3VO4. Sodium fluoride or Na3VO4 were added either separately or together to the 
biotinylation reaction mixtures as indicated above each panel. Each reaction was 
incubated for 30 min at 37 °C after which time point 1 µl of each reaction was spotted 
onto a cellulose thin layer chromatography plate. Following plate development the 
reaction products (indicated by arrows), biotinoyl-5ʹ′-AMP (Bio-5ʹ′-AMP), ADP, AMP 
and the remaining ATP were visualized by autoradiography. NE denotes the control 
reactions lacking BirA. The identities of the spots are given on the left margin.  
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Figure 3.8. Isolation and characterization of BirA 10b mutant exhibiting 
superrepressor phenotypes. Single colonies were streaked on defined medium plates 
supplemented with 1.6 nM biotin and X-Gal for phenotypic confirmation. Liquid cultures 
grown in the same medium without X-Gal were then assayed for bio operon transcription 
by β-galactosidase activity (Materials and Methods). The birA inserts of the plasmids 
encoding the superrepressor BirAs were then sequenced. Each of the constructs were 
expressed form a medium copy number plasmid pVC7 in which a constitutive promoter 
drives birA expression. Panel A shows the deconvolution of the 10b triple mutant to 
identify the mutation causing the superrepressor phenotype. Note that the data are plotted 
on the Y-axis as a log scale. The results show the average of three independent 
experiments and the error bars denote the standard error. The mutations were generated 
by site-directed mutagenesis (Materials and Methods). Panel B shows the three-
dimensional structure of monomeric BirA protein. The amino-acid substitutions that 
resulted in the 10b mutant are highlighted. The model was constructed using Chimera 
(86) and PDB file 1HXD.  
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Figure 3.9. Genetic evidence that the wing plays a direct role in the enzymatic 
function of BirA. In Panel A, transcription of the bio operon in cultures grown with 4 
nM biotin (derepression conditions; depicted with solid bars) or 4 µM biotin (repression 
conditions; depicted by open bars) assayed by β-galactosidase production from a 
chromosomal bioF::lacZY fusion. The strains used were derivatives of strain VC618 
cured of plasmid pVC18 (8). Single colonies were streaked on defined medium plates 
supplemented with 4 nM biotin and X-gal for phenotypic confirmation. Liquid cultures 
were grown in the same medium lacking X-gal and were then assayed for bio operon 
transcription by β-galactosidase activity (Materials and Methods).  The results show the 
average of three independent experiments and the error bars denote the standard error. 
Note that the data are plotted on the y-axis as a log scale. In Panel B, three-dimensional 
structure of monomeric BirA protein is shown. The single residue substitutions tested are 
highlighted. The model was constructed using Chimera (86) and Protein Data Bank file 
1HXD. 
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CHAPTER 4 
 
CONCLUSIONS 
 The goal of this thesis has been to understand the transcriptional regulation of the 
biotin operon and the biotinylation function by the E. coli BirA biotin protein ligase. The 
BirA transcriptional regulation activity is biotin-dependent repression of the bioABFCD 
biotin synthetic operon, while the enzymatic activity of BirA is ligation of biotin to its 
cognate proteins. BirA is a unique transcriptional regulator in that it synthesizes its own 
regulatory ligand from biotin and ATP. That is, the key player in BirA regulation is not 
biotin, but rather is biotinoyl-5ʹ-AMP (Bio-5ʹ′-AMP), the intermediate of the ligation 
reaction (15, 35, 89). Co-repressor binding triggers major conformational changes within 
BirA that are harnessed to elicit transcriptional regulation. However, the specific inter-
domains communication within the protein that allows it to process the intracellular cues 
(biotin concentration and apo-protein concentration) and coordinate its two function are 
still unknown. Moreover, the absence of a co-crystal structure of BirA-corepressor-DNA 
has impeded our ability to (a) identify the key amino acid residues that are directly 
involved in interaction with the DNA and (b) understand the structural remodeling of the 
domains that occurs as the protein transitions from a ligase to a regulator and visa versa. 
In an attempt to gain greater insight into this intricate system I isolated and characterized 
a new class of mutants called superrepressor mutants of BirA (Chapter 2). In Chapter 3, I 
carried out subsequent studies to define the role of the N-terminal domain in the 
biotinylation and DNA binding function of the protein.  
 Crystallization studies are inherently based on trial and error and require a great 
deal of optimization that make the screening options limitless. The studies carried out to 
isolate superrepressor mutants (Chapter 2) were initiated to aid in the isolation of co-
crystal structure of BirA bound to DNA. In collaboration with Dr. Satish Nair and his 
graduate student Dr. Vinayak Agarwal, I set up several screens with BirA superrepressor 
mutants along with DNA encoding the bio operator. We were successful in obtaining 
crystals for some of the conditions that we tested (Chapter 2). However, none of the 
crystals diffracted, and we were unable to obtain any usual data to extrapolate the 
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coordinates for the structure. For future co-crystallization experiments I would 
recommend using BPL from either Staphylococcus aureus or Bacillus subtilis. Both these 
BPLs belong to the bifunctional group II enzyme similar to E. coli; however they have 
distinct differences that might aid in the isolation of co-crystal structures. Primarily, since 
the DNA binding sites recognized by both these BPLs are different from the E. coli bio 
operator and, secondly, these two proteins share only ~20% amino acid similarity with E. 
coli BirA, these key differences between the BPLs could aid in the crystallization studies. 
 The key mechanistic and structural differences highlighted in Chapter 1 between 
Class I and Class II BPL make the bacterial BPLs potential targets to develop antibiotics. 
Structural studies are important, because they provide detailed understanding of the 
functional interfaces of Class II BPL with their substrates. Based on the essential role of 
the BPL in the survival of these microorganisms, BPLs pose as unique targets for 
developing small molecule inhibitors that specifically target these proteins in pathogenic 
microorganisms. Structural studies were important in the designing of a unique small 
molecule inhibitor that showed selective inhibition of SaBPL over both EcBPL and HCS 
(100). Therefore it is important that attempts to screen new candidates for the co-
crystallization studies are continued for Class II BPLs. 
 In E. coli, the BirA biotin protein ligase biotinylates only a single protein, AccB, a 
subunit of acetyl CoA carboxylase, the enzyme responsible for the first step of fatty acid 
synthesis. The ligase reaction proceeds in an ordered manner in which the monomeric 
enzyme first binds biotin and then ATP, resulting in synthesis of biotinoyl-adenylate 
(121), which triggers formation of the BirA dimers required for DNA binding (105). The 
dimeric BirA biotinoyl-adenylate complex regulates transcription by binding to the biotin 
operator (bioO), a 40-bp inverted repeat that overlaps both biotin operon promoters (104). 
The transition of BirA from a ligase to a repressor depends on both the intracellular biotin 
concentration and the level of unbiotinylated AccB (35, 36, 101). Maximal rates of bio 
operon transcription (derepression) occur when the biotin supply is severely limited (e.g., 
biotin starvation of a bio auxotroph) or when high levels of a biotin acceptor protein are 
present (Figure 2.1C and D). Under these conditions any biotinoyl-adenylate synthesized 
is rapidly consumed in biotinylation of the acceptor protein (AccB) and hence no 
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significant levels of the BirA:biotinoyl-adenylate complex accumulate. Hence, BirA 
remains largely monomeric, and thus the bio operator is seldom occupied and 
transcription is maximal. Repression of bio operon transcription occurs when the supply 
of biotin is in excess of that needed to biotinylate AccB. Under these conditions, AccB 
becomes fully biotinylated and the BirA:biotinoyl-adenylate complex accumulates. 
Binding of biotinoyl-adenylate results in conversion of BirA monomers to the repressing 
dimeric species. The dimeric complex then binds the bio operator and represses 
transcription from both promoters. The two conditions resulting in derepression act by 
the common mechanism in that both decrease the levels of the BirA:biotinoyl-adenylate 
complex available to bind the bio operator. Hence, the degree of repression of bio operon 
transcription can be most simply viewed as an antagonism between retention of biotinoyl-
adenylate in the BirA active site versus consumption of the biotinoyl-adenylate bound to 
BirA by transfer of the biotinoyl moiety to unmodified acceptor proteins (35, 101).  
 What then is the molecular switch and how is it regulated? The competing 
protein-protein interaction model, initially proposed by Weaver et al. (113) postulates 
that the unmodified acceptor protein binds the monomeric BirA:biotinoyl-5ʹ -AMP 
complex and thereby blocks assembly (dimerization) of the form of BirA that binds 
DNA. Therefore the unmodified acceptor protein binds a monomeric BirA complex and 
thereby impedes the formation of BirA dimers; the species required for repression, 
providing a structural context for this antagonism. Based on this model one would expect 
that the heterodimer must be sufficiently long-lived to compete with homodimerization of 
BirA:bio-AMP, and, thus, as in the case of the homodimer, direct detection of the 
heterodimer might be expected. However, direct detection of the AccB plus BirA:bio-
AMP heterodimer has not been reported, and only indirect evidence for its existence is 
available (124). The data of Solbiati and Cronan (101) using peptide substrates by Schatz 
(97) argue strongly against this mechanism. These peptides have no sequence similarity 
to the natural acceptor protein and do not require the extensive protein-protein 
interactions postulated in the above model. These peptides were shown to be as efficient 
in the derepression of the bio operon transcription as the acceptor protein (101), 
suggesting that BirA binds to these peptides in a different manner. Because the rate of bio 
operon transcription is sensitive not only to the intracellular concentration of biotin, but 
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also to the supply of the protein to which the biotin must be attached, the net result of 
accumulation of the unmodified protein is an increase in the rate of synthesis of the small 
molecule (Bio-5ʹ′-AMP) needed for the post-translational modification (36). Hence, the 
switch is the removal of Bio-5ʹ′-AMP from the BirA active site by protein biotinylation, 
previously proposed by Cronan in 1989 (35), and, thus, AccB (or the Schatz peptides) 
would act only as classic enzyme substrates in which the interaction between the acceptor 
substrate and BirA is brief.  
 Based on protein-protein competition model by Adikaram and Beckett (2) 
mutants of BirA that are unable to biotinylate AccB should also be unable to modify the 
acceptor peptide because the interface required for the postulated heterodimer is the same 
and it is competing for the homodimer formation. On the other hand, mutants of BirA 
that are unable to biotinylate the acceptor protein and are still able to biotinylate the 
peptide would imply that the regulatory switch does not depend on the extensive 
interaction between BirA and the acceptor protein. The results from Solbiati and Cronan 
(101) are consistent with this model, but this hypothesis requires further testing. By 
modifying the selection and screening approach that I designed in the Chapter 2, one can 
isolate these BirA mutants.  
 Finally, in Chapter 3 I showed that the wing not only plays the expected role in 
DNA binding but also organizes the enzyme active site and thus provides the first 
example of a wHTH structure that participates in enzyme catalysis. This study helped 
dissect the structural and functional role of the wing of the wHTH motif in both BirA 
functions. The ability of the T52S mutation to restore repression to otherwise repression-
defective biotin binding loop mutants shows a direct interaction between the wing and the 
catalytic site of the protein. These results together clearly depict the long-range 
communication within BirA.  However, the exact positioning of the wing as it transitions 
to the regulatory state and binds to the DNA remains unknown; moreover, the role of the 
wing in interacting with the acceptor protein still remains to be investigated.  
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